Combination treatment for hematological cancers
A combination of Imetelstat sodium and ABT-199 induces apoptosis in leukemia cells, addressing the limitations of current AML treatments by enhancing efficacy and reducing relapse, providing a novel therapeutic option for AML.
Patent Information
- Application Number
- JP2024154746
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2016-11-16
- Filing Date
- 2024-09-09
- Publication Date
- 2024-11-28
AI Technical Summary
Patients with acute myeloid leukemia (AML) have limited treatment options, and current chemotherapy approaches often lead to relapse due to the rapid killing of healthy bone marrow cells, causing disease and requiring further palliative treatments.
A combination therapy using a telomerase inhibitor, such as Imetelstat sodium, and a Bcl-2 inhibitor, such as ABT-199, to induce apoptosis in leukemia cells, potentially overcoming drug resistance and enhancing treatment efficacy.
The combination of Imetelstat sodium and ABT-199 promotes significant apoptosis in leukemia cells, offering a novel treatment approach with potential for improved response rates and reduced toxicity compared to single-agent therapies.
Smart Images

Figure 2024166290000032 
Figure 2024166290000033 
Figure 2024166290000034
Abstract
Description
[Technical field]
[0001] (CROSS REFERENCE TO RELATED APPLICATIONS) This application claims priority to U.S. Provisional Application No. 62 / 370,018, filed August 2, 2016, European Patent Application No. 16197293.0, filed November 4, 2016, and U.S. Provisional Application No. 62 / 422,738, filed November 16, 2016, the entire contents of each of which are incorporated herein by reference.
[0002] (Sequence Listing) This application contains a Sequence Listing that has been submitted electronically in ASCII format and is incorporated herein by reference in its entirety. This ASCII copy was created on July 17, 2017, is named PRD3424WOPCT_SL.txt, and is 2,335 bytes in size.
[0003] FIELD OF THEINVENTION The present disclosure provides for the treatment of hematological cancers with a combination of a telomerase inhibitor and a Bcl-2 inhibitor. [Background technology]
[0004] BACKGROUND OF THEINVENTION Patients with acute myeloid leukemia (AML) have limited treatment options at the time of diagnosis. Treatment typically takes the form of chemotherapy to rapidly reduce the leukemic cell burden. Invasive leukapheresis procedures to remove large numbers of white blood cells (normal and diseased) may be applied in parallel with chemotherapy to temporarily lower the tumor cell burden. Induction phase chemotherapy may be successful, but most remaining healthy cells in the patient's bone marrow also die, causing disease, necessitating further palliative treatments to avoid infections and raise the white blood cell count. Chemotherapy may be used further in an attempt to keep the patient in remission, but relapse is common.
[0005] Telomerase is present in over 90% of tumors across all types of cancer and is absent in normal healthy tissues. Imetelstat sodium is a novel, first-in-class telomerase inhibitor that is a covalently lipidated 13-mer oligonucleotide (shown below) complementary to the human telomerase RNA (hTR) template region. Imetelstat sodium does not function by antisense mechanism and therefore is free of the side effects commonly seen with such treatments. Imetelstat sodium is the sodium salt of imetelstat (shown below). [ka] Imetelstat sodium Unless otherwise indicated or clear from the context, references below to Imetelstat also include its salts. As mentioned above, Imetelstat sodium is specifically the sodium salt of Imetelstat.
[0006] ABT-199 / venetoclax (brand name Venclexta) is an FDA approved Bcl-2 inhibitor for use in patients with relapsed / refractory chronic lymphocytic leukemia (CLL) with del17p. ABT-199 is also known as ABT 199, GDC0199, GDC-0199 or RG7601. The chemical name of ABT-199 is 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide (Cas number 1257044-40-8). Unless otherwise indicated or clear from the context, references hereinafter to ABT-199 also include pharma- ceutically acceptable salts thereof, but specifically in the examples ABT-199 was used in its free base form.
[0007] ABT-199, shown below in free base form, is highly specific for Bcl-2, exhibiting affinity for related Bcl family members and distinct from other first generation inhibitors that induce significant side effects. Inhibition of Bcl-2 blocks pro-apoptotic signals triggered by damage or abnormalities in cellular DNA, ultimately inducing programmed cell death via the caspase cascade and apoptosis via the intrinsic pathway in treated cells. [ka] ABT-199 (shown in free base form) Summary of the Invention [Means for solving the problem]
[0008] In AML cells, the combined administration of imetelstat sodium and ABT-199 provides a novel treatment for hematological cancers, particularly AML. Imetelstat sodium is currently being clinically investigated in myelofibrosis (MF) and myelodysplastic syndromes (MDS). ABT-199 is FDA approved for CLL and is also being studied in AML.
[0009] When administered in combination, these two agents can promote apoptosis in cancer cells.When administered in combination, these two agents can treat cancer in a subject in need of treatment.
[0010] Thus, one embodiment of the present invention is a method of treating hematological cancer comprising administering to a subject in need of treatment a combination of a telomerase inhibitor and a Bcl-2 inhibitor.
[0011] In one embodiment of the method, the telomerase inhibitor is imetelstat. In another embodiment, the imetelstat is imetelstat sodium. Imetelstat or imetelstat sodium may be administered in 1, 2, 3, 4, 5, 6, 7, 8, or more than 8 dosing cycles, each cycle comprising: (a) about 7-10 mg / kg of imetelstat administered intravenously once every 4 weeks; (b) about 7-10 mg / kg of imetelstat administered intravenously once a week for 4 weeks; (c) about 2.5-10 mg / kg of imetelstat administered intravenously once every 3 weeks; or (d) about 0.5-9.4 mg / kg of imetelstat administered intravenously once every 4 weeks.
[0012] This treatment approach is applicable to acute myeloid leukemia, essential thrombocythemia, polycythemia vera, primary myelofibrosis, systemic mastocytosis, chronic myeloid leukemia, chronic neutrophilic leukemia, chronic eosinophilic leukemia, refractory anemia with ringed sideroblasts, refractory cytopenia with polycythemia vera, refractory anemia with excessive blasts (type 1), refractory anemia with excessive blasts (type 2), myelodysplastic syndrome (MDS) with isolated del (5q), unclassifiable MDS, and chronic myelomonocytic leukemia. (CML), atypical chronic myeloid leukemia, juvenile myelomonocytic leukemia, unclassifiable myeloproliferative / myelodysplastic syndrome, B-lymphoblastic leukemia / lymphoma, T-lymphoblastic leukemia / lymphoma, diffuse large B-cell lymphoma, primary central nervous system lymphoma, primary mediastinal B-cell lymphoma, Burkitt's lymphoma / leukemia, follicular lymphoma, chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma, B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma / Waldenström macroglobulinemia, mantle cell lymphoma, marginal zone lymphoma, post-transplant lymphoproliferative disorder, HIV-associated lymphoma, primary effusion lymphoma, intravascular large B-cell lymphoma, primary cutaneous B-cell lymphoma The present invention may be used to treat hematological cancers selected from acute myeloid leukemia, idiopathic lymphoma, hairy cell leukemia, monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and solitary plasmacytoma (isolated bone and extramedullary). In one embodiment, the hematological cancer is acute myeloid leukemia. Thus, one embodiment of the present invention is a method of treating acute myeloid leukemia, comprising administering imetelstat and ABT-199 to a subject with acute myeloid leukemia.
[0013] Another embodiment of the invention is a method of inducing apoptosis in hematological cancer cells, comprising contacting the cells with a therapeutically effective amount of a telomerase inhibitor and contacting the cells with a therapeutically effective amount of a Bcl-2 inhibitor. In certain embodiments, the telomerase inhibitor is imetelstat or imetelstat sodium. In certain embodiments, particularly when imetelstat is used, the Bcl-2 inhibitor is ABT-199. In certain embodiments, the hematological cancer cells are selected from the group consisting of acute myeloid leukemia, essential thrombocythemia, polycythemia vera, primary myelofibrosis, systemic mastocytosis, chronic myeloid leukemia, chronic neutrophilic leukemia, chronic eosinophilic leukemia, refractory anemia with ringed sideroblasts, refractory cytopenia with polycythemia dysplasia, refractory anemia with excess blasts (type 1), refractory anemia with excess blasts (type 2), myelodysplastic syndrome (MDS) with isolated 5q deletion, unclassifiable MDS, chronic myelomonocytic leukemia (CML), atypical chronic myeloid leukemia, juvenile myelomonocytic leukemia, unclassifiable myeloproliferative / myelodysplastic syndrome, B-lymphoblastic leukemia / lymphoma, T-lymphoblastic leukemia, and / or T-lymphoblastic leukemia. The cancer cells are selected from hematology / lymphoma, diffuse large B-cell lymphoma, primary central nervous system lymphoma, primary mediastinal B-cell lymphoma, Burkitt's lymphoma / leukemia, follicular lymphoma, chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma, B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma / Waldenström macroglobulinemia, mantle cell lymphoma, marginal zone lymphoma, post-transplant lymphoproliferative disorder, HIV-associated lymphoma, primary effusion lymphoma, intravascular large B-cell lymphoma, primary cutaneous B-cell lymphoma, hairy cell leukemia, monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and isolated plasmacytoma (isolated bone and extramedullary). In one embodiment, the hematological cancer cells are acute myeloid leukemia (AML) cells.
[0014] The method of inducing apoptosis may be performed in vivo or in vitro. Thus, one embodiment of the present invention is an in vitro method of inducing apoptosis in acute myeloid leukemia (AML) cells, comprising contacting the cells with a therapeutically effective amount of imetelstat sodium and contacting the cells with a therapeutically effective amount of ABT-199. In another embodiment, the method comprises administering to a subject with a hematological cancer a therapeutically effective amount of a telomerase inhibitor and a Bcl-2 inhibitor.
[0015] Another embodiment of the present invention is a kit comprising a telomerase inhibitor (e.g., imetelstat) in a dose amount effective to induce apoptosis in hematological cancer cells when administered, and a Bcl-2 inhibitor (e.g., ABT-199) in a dose amount effective to induce apoptosis in hematological cancer cells when administered. In yet another embodiment, the present invention relates to a pharmaceutical composition comprising imetelstat or imetelstat sodium and ABT-199. The composition may be formulated for the treatment of acute myeloid leukemia.
[0016] The present invention also encompasses the use of imetelstat or imetelstat sodium to treat hematological cancers in patients undergoing BCL inhibitor therapy. In another embodiment, the present invention relates to the use of ABT-199 to treat hematological cancers in patients undergoing telomerase inhibitor therapy.
[0017] Alternative embodiments of the invention relate to: (1) a telomerase inhibitor (e.g., imetelstat or imetelstat sodium) for use in a method of treating a hematological cancer, the method comprising administering said telomerase inhibitor in combination with a Bcl-2 inhibitor (e.g., ABT-199) to a subject in need of treatment, or (2) a combination comprising a telomerase inhibitor (e.g., imetelstat or imetelstat sodium) and a Bcl-2 inhibitor (e.g., Bcl-2) for use in a method of treating a hematological cancer, the method comprising administering the combination to a subject in need of treatment. In these embodiments, the hematological cancer may be acute myeloid leukemia. or blood cancers include acute myeloid leukemia (AML), essential thrombocythemia, polycythemia vera, primary myelofibrosis, systemic mastocytosis, chronic myeloid leukemia, chronic neutrophilic leukemia, chronic eosinophilic leukemia, refractory anemia with ringed sideroblasts, refractory cytopenia with polycythemia dysplasia, refractory anemia with excess blasts (type 1), refractory anemia with excess blasts (type 2), myelodysplastic syndromes (MDS) with isolated deletion of the long arm of chromosome 5 (5q), unclassifiable MDS, chronic myelomonocytic leukemia (CML), atypical chronic myeloid leukemia, juvenile myelomonocytic leukemia, unclassifiable myeloproliferative / myelodysplastic syndrome, B lymphoblastic leukemia / lymphoma, T lymphoblastic leukemia / lymphoma , diffuse large B-cell lymphoma, primary central nervous system lymphoma, primary mediastinal B-cell lymphoma, Burkitt's lymphoma / leukemia, follicular lymphoma, chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma, B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma / Waldenstrom's macroglobulinemia, mantle cell lymphoma, marginal zone lymphoma, post-transplant lymphoproliferative disorder, HIV-associated lymphoma, primary effusion lymphoma, intravascular large B-cell lymphoma, primary cutaneous B-cell lymphoma, hairy cell leukemia, monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and solitary plasmacytoma (isolated bone and extramedullary). In these embodiments, the combination of the telomerase inhibitor and the Bcl-2 inhibitor induces apoptosis of blood cancer cells.
[0018] Further embodiments of the present invention relate to: (1) imetelstat sodium for use in a method for treating acute myeloid leukemia (AML), the method comprising administering imetelstat sodium in combination with ABT-199 to a subject in need of treatment, (2) ABT-199 for use in a method for treating acute myeloid leukemia (AML), the method comprising administering imetelstat sodium in combination with ABT-199 to a subject in need of treatment, or (3) a combination comprising imetelstat sodium and ABT-199 for use in a method for treating acute myeloid leukemia (AML), the method comprising administering the combination to a subject in need of treatment. In these embodiments, the imetelstat sodium is for administration for 1, 2, 3, 4, 5, 6, 7, 8, or more than 8 dosing cycles, each cycle comprising: (a) about 7-10 mg / kg of imetelstat sodium administered intravenously once every 4 weeks; (b) about 7-10 mg / kg of imetelstat sodium administered intravenously once per week for 4 weeks; (c) about 2.5-7 mg / kg of imetelstat sodium administered intravenously once every 3 weeks; or (d) about 0.5-9.4 mg / kg of imetelstat sodium administered intravenously once every 4 weeks. Further, in these embodiments, ABT-199 is for administration: (a) at a dose of about 50-400 mg of ABT-199 daily; (b) at a dose of about 2 mg of ABT-199 on day 1, increasing daily thereafter to a final dose of about 800 mg on day 6, and at that final dose daily thereafter; or (c) at a dose of about 25 mg of ABT-199 on day 1, increasing daily thereafter to a final dose of about 400 mg on day 5, and at that final dose daily thereafter. Also, in these embodiments, administration of ABT-199 may be one day prior to, one day after, or on the same day as administration of imetelstat sodium. [Brief description of the drawings]
[0019] [Figure 1A]FIG. 1A shows the effect of treating KG-1 cells with imetelstat sodium and / or ABT-199 for 48 hours. [Figure 1B] FIG. 1B shows the effect of treating KG-1 cells with imetelstat sodium and / or ABT-199 for 48 hours. FIG. 1A shows a dot plot of KG-1 cells after treatment with various concentrations of ABT-199 and / or imetelstat sodium for 48 hours and stained with Annexin V and propidium iodide. FIG. 1B shows a graph of % apoptotic cells as a concentration of compound when KG-1 cells are treated with various concentrations of ABT-199 and / or imetelstat sodium for 48 hours. Apoptotic cells are double labeled with Annexin V and propidium iodide. [Figure 2A] FIG. 2A shows the effect of treating KG-1 cells with imetelstat sodium and / or ABT-199 for 96 hours. [Figure 2B] Figure 2B shows the effect of treating KG-1 cells with imetelstat sodium and / or ABT-199 for 96 hours. Figure 2A shows a dot plot of KG-1 cells after treatment with various concentrations of ABT-199 and / or imetelstat sodium for 96 hours and stained with Annexin V and propidium iodide. Figure 2B shows a graph of % apoptotic cells as a concentration of compound when KG-1 cells are treated with various concentrations of ABT-199 and / or imetelstat sodium for 96 hours. Apoptotic cells are double labeled with Annexin V and propidium iodide. [Figure 3A] FIG. 3A shows the effect of treating KG-1 cells with mismatched or non-complementary oligonucleotides and ABT-199 for 48 hours. [Figure 3B]FIG. 3B shows the effect of treating KG-1 cells with mismatched or non-complementary oligonucleotides and ABT-199 for 48 hours. FIG. 3A shows dot plots of KG-1 cells after treatment with various concentrations of ABT-199 and / or control oligonucleotides for 48 hours and stained with Annexin V and propidium iodide. FIG. 3B shows a graph of % apoptotic cells as a compound concentration when KG-1 cells are treated with various concentrations of ABT-199 and / or control oligonucleotides for 48 hours. Non-Comp refers to non-complementary control oligonucleotide. Apoptotic cells are double labeled with Annexin V and propidium iodide. [Figure 4A] FIG. 4A shows the effect of treating KG-1 cells with mismatched or non-complementary oligonucleotides and ABT-199 for 96 hours. [Figure 4B] FIG. 4B shows the effect of treating KG-1 cells with mismatched or non-complementary oligonucleotides and ABT-199 for 96 hours. FIG. 4A shows dot plots of KG-1 cells after treatment with various concentrations of ABT-199 and / or control oligonucleotides for 96 hours and stained with Annexin V and propidium iodide. FIG. 4B shows a graph of % apoptotic cells as a compound concentration when KG-1 cells are treated with various concentrations of ABT-199 and / or control oligonucleotides for 48 hours. Non-Comp refers to non-complementary control oligonucleotide. Apoptotic cells are double labeled with Annexin V and propidium iodide. [Figure 5A] FIG. 5A shows the effect of treating MOLM-13 cells with imetelstat sodium and / or ABT-199 for 48 hours. [Figure 5B]Figure 5B shows the effect of treating MOLM-13 cells with imetelstat sodium and / or ABT-199 for 48 hours. Figure 5A shows a dot plot of MOLM-13 cells after treatment with various concentrations of ABT-199 and / or imetelstat sodium for 48 hours and stained with Annexin V and propidium iodide. Figure 5B shows a graph of % apoptotic cells as a function of compound concentration when MOLM-13 cells are treated with various concentrations of ABT-199 and / or imetelstat sodium for 48 hours. Apoptotic cells are double labeled with Annexin V and propidium iodide. [Figure 6A] FIG. 6A shows the effect of treating MOLM-13 cells with imetelstat sodium and / or ABT-199 for 48 hours. [Figure 6B] Figure 6B shows the effect of treating MOLM-13 cells with imetelstat sodium and / or ABT-199 for 48 hours. Figure 6A shows a dot plot of MOLM-13 cells after treatment with various concentrations of ABT-199 and / or imetelstat sodium for 96 hours and stained with Annexin V and propidium iodide. Figure 6B shows a graph of % apoptotic cells as a function of compound concentration when MOLM-13 cells are treated with various concentrations of ABT-199 and / or imetelstat sodium for 96 hours. Apoptotic cells are double labeled with Annexin V and propidium iodide. [Figure 7A] FIG. 7A shows the effect of treating MOLM-13 cells with various concentrations of ABT-199 and / or control oligonucleotides for 48 hours. [Figure 7B]FIG. 7B shows the effect of treating MOLM-13 cells with various concentrations of ABT-199 and / or control oligonucleotides for 48 hours. FIG. 7A shows a dot plot of MOLM-13 cells after treatment with various concentrations of ABT-199 and / or control oligonucleotides for 48 hours and stained with Annexin V and propidium iodide. FIG. 7B shows a graph of % apoptotic cells as a compound concentration when MOLM-13 cells are treated with various concentrations of ABT-199 and / or control oligonucleotides for 48 hours. Non-Comp refers to non-complementary control oligonucleotides. Apoptotic cells are double labeled with Annexin V and propidium iodide. [Figure 8A] FIG. 8A shows the effect of treating MOLM-13 cells with various concentrations of ABT-199 and / or control oligonucleotides for 96 hours. [Figure 8B] FIG. 8B shows the effect of treating MOLM-13 cells with various concentrations of ABT-199 and / or control oligonucleotides for 96 hours. FIG. 8A shows a dot plot of MOLM-13 cells after treatment with various concentrations of ABT-199 and / or control oligonucleotides for 96 hours and stained with Annexin V and propidium iodide. FIG. 8B shows a graph of % apoptotic cells as a compound concentration when MOLM-13 cells are treated with various concentrations of ABT-199 and / or control oligonucleotides for 96 hours. Non-Comp refers to non-complementary control oligonucleotides. Apoptotic cells are double labeled with Annexin V and propidium iodide. [Figure 9] FIG. 9 shows hTERT transcript levels measured by RT-qPCR in KG-1 or MOLM-13 cells after 48 and 96 hours of treatment with imetelstat sodium, ABT-199, or the combination. [Figure 10]FIG. 10 shows telomerase enzyme activity levels measured by qPCR TRAP in KG-1 or MOLM-13 cells after 48 and 96 hours of treatment with imetelstat sodium, ABT-199, or the combination. [Figure 11] 11 shows a graph of % apoptotic cells as a function of compound concentration when MOLM-13 cells were treated with various concentrations of ABT-199 and / or imetelstat sodium for 48 hours. Apoptotic cells were double labeled with Annexin V and propidium iodide. [Figure 12A] FIG. 12A shows a graph of % apoptotic cells as a function of compound concentration when MOLM-13 cells were treated with various concentrations of ABT-199, control mismatch oligonucleotides, and non-complementary oligonucleotides for 48 hours. [Figure 12B] Figure 12B shows a graph of % apoptotic cells as a compound concentration when MOLM-13 cells are treated with various concentrations of ABT-199, control mismatch oligonucleotides, and non-complementary oligonucleotides for 48 hours. Figure 12A shows a graph of % apoptotic cells as a compound concentration when MOLM-13 cells are treated with various concentrations of ABT-199 and / or control mismatch oligonucleotides "Mismatch" for 48 hours. Figure 12B shows a graph of % apoptotic cells as a compound concentration when MOLM-13 cells are treated with various concentrations of ABT-199 and / or control non-complementary oligonucleotides "Non-comp" for 48 hours. Apoptotic cells are double labeled with Annexin V and propidium iodide. [Figure 13] 13 shows a graph of % apoptotic cells as a function of compound concentration when MOLM-13 cells were treated with various concentrations of ABT-199 and / or imetelstat sodium for 96 hours. Apoptotic cells were double labeled with Annexin V and propidium iodide. [Figure 14A]FIG. 14A shows a graph of % apoptotic cells as a function of compound concentration when MOLM-13 cells were treated with various concentrations of ABT-199, control mismatch oligonucleotides, and non-complementary oligonucleotides for 48 hours. [Figure 14B] Figure 14B shows a graph of % apoptotic cells as a compound concentration when MOLM-13 cells are treated with various concentrations of ABT-199, control mismatch oligonucleotides, and non-complementary oligonucleotides for 48 hours. Figure 14A shows a graph of % apoptotic cells as a compound concentration when MOLM-13 cells are treated with various concentrations of ABT-199 and / or control mismatch oligonucleotides "Mismatch" for 96 hours. Figure 14B shows a graph of % apoptotic cells as a compound concentration when MOLM-13 cells are treated with various concentrations of ABT-199 and / or control non-complementary oligonucleotides "Non-comp" for 96 hours. Apoptotic cells are double labeled with Annexin V and propidium iodide. [Figure 15A]Figures 15A-15D show the average response of four PBMC (peripheral blood mononuclear cell) samples purified from whole blood of AML patients, exposed ex vivo to treatment with ABT-199 and / or imetelstat sodium at various concentrations for 16 and 40 hours, and analyzed for cell viability by flow cytometry assays after staining with Annexin V and propidium iodide. Figures 15A and 15B show graphs of % viable cells as a function of compound concentration when Ficoll-purified PBMCs from whole blood of AML patients were treated with various concentrations of ABT-199 and / or imetelstat sodium for 16 hours. Figure 15A shows the results for CD45+ leukocytes. Figure 15B shows the results for CD45+ / CD34+ leukemia stem cells. Figures 15C and 15D show graphs of % viable cells as a function of compound concentration when Ficoll-purified PBMCs from whole blood of AML patients were treated with various concentrations of ABT-199 and / or imetelstat sodium for 40 hours. Figure 15C shows the results for CD45+ leukocytes. Figure 15D shows the results for CD45+ / CD34+ leukemia stem cells. In Figures 15A-15D, error bars represent standard deviation. Viable cells remaining after treatment are not labeled with either Annexin V or Propidium Iodide. [Figure 15B]Figures 15A-15D show the average response of four PBMC (peripheral blood mononuclear cell) samples purified from whole blood of AML patients, exposed ex vivo to treatment with ABT-199 and / or imetelstat sodium at various concentrations for 16 and 40 hours, and analyzed for cell viability by flow cytometry assays after staining with Annexin V and propidium iodide. Figures 15A and 15B show graphs of % viable cells as a function of compound concentration when Ficoll-purified PBMCs from whole blood of AML patients were treated with various concentrations of ABT-199 and / or imetelstat sodium for 16 hours. Figure 15A shows the results for CD45+ leukocytes. Figure 15B shows the results for CD45+ / CD34+ leukemia stem cells. Figures 15C and 15D show graphs of % viable cells as a function of compound concentration when Ficoll-purified PBMCs from whole blood of AML patients were treated with various concentrations of ABT-199 and / or imetelstat sodium for 40 hours. Figure 15C shows the results for CD45+ leukocytes. Figure 15D shows the results for CD45+ / CD34+ leukemia stem cells. In Figures 15A-15D, error bars represent standard deviation. Viable cells remaining after treatment are not labeled with either Annexin V or Propidium Iodide. [Figure 15C]Figures 15A-15D show the average response of four PBMC (peripheral blood mononuclear cell) samples purified from whole blood of AML patients, exposed ex vivo to treatment with ABT-199 and / or imetelstat sodium at various concentrations for 16 and 40 hours, and analyzed for cell viability by flow cytometry assays after staining with Annexin V and propidium iodide. Figures 15A and 15B show graphs of % viable cells as a function of compound concentration when Ficoll-purified PBMCs from whole blood of AML patients were treated with various concentrations of ABT-199 and / or imetelstat sodium for 16 hours. Figure 15A shows the results for CD45+ leukocytes. Figure 15B shows the results for CD45+ / CD34+ leukemia stem cells. Figures 15C and 15D show graphs of % viable cells as a function of compound concentration when Ficoll-purified PBMCs from whole blood of AML patients were treated with various concentrations of ABT-199 and / or imetelstat sodium for 40 hours. Figure 15C shows the results for CD45+ leukocytes. Figure 15D shows the results for CD45+ / CD34+ leukemia stem cells. In Figures 15A-15D, error bars represent standard deviation. Viable cells remaining after treatment are not labeled with either Annexin V or Propidium Iodide. [Figure 15D]Figures 15A-15D show the average response of four PBMC (peripheral blood mononuclear cell) samples purified from whole blood of AML patients, exposed ex vivo to treatment with ABT-199 and / or imetelstat sodium at various concentrations for 16 and 40 hours, and analyzed for cell viability by flow cytometry assays after staining with Annexin V and propidium iodide. Figures 15A and 15B show graphs of % viable cells as a function of compound concentration when Ficoll-purified PBMCs from whole blood of AML patients were treated with various concentrations of ABT-199 and / or imetelstat sodium for 16 hours. Figure 15A shows the results for CD45+ leukocytes. Figure 15B shows the results for CD45+ / CD34+ leukemia stem cells. Figures 15C and 15D show graphs of % viable cells as a function of compound concentration when Ficoll-purified PBMCs from whole blood of AML patients were treated with various concentrations of ABT-199 and / or imetelstat sodium for 40 hours. Figure 15C shows the results for CD45+ leukocytes. Figure 15D shows the results for CD45+ / CD34+ leukemia stem cells. In Figures 15A-15D, error bars represent standard deviation. Viable cells remaining after treatment are not labeled with either Annexin V or Propidium Iodide. [Figure 16]Figure 16 shows the in vivo antitumor efficacy and survival benefit of imetelstat sodium or ABT-1 as monotherapy, or both agents in combination, in a mouse model. Mice were seeded with MOLM-13 cells (disseminated model) and treated with vehicle, imetelstat sodium and / or ABT-199, or mismatched oligonucleotide control and ABT-199. Mice were monitored for survival after treatment (n=10 mice / group at start). Specifically, Figure 16 shows mouse survival as a function of days after tumor cell implantation. Mice were treated for 31 days with: (i) vehicle (MM+PEG400 / Phosal50 / ETOH); (ii) imetelstat sodium (30 mg / kg), (iii) ABT-199 (100 mg / kg), (iv) MM(mismatch oligo) (30 mg / kg) and ABT-199 (100 mg / kg); and (v) imetelstat sodium (30 mg / kg) and ABT-199 (100 mg / kg). [Figure 17A] FIG. 17A shows the apoptotic populations 96 hours after a single dose of imetelstat sodium treatment for MOLM-13 and HL-60 cells. [Figure 17B] Figure 17B shows the apoptotic population 96 hours after one dose of imetelstat sodium treatment for MOLM-13 cells and HL-60 cells. Figure 17A shows the apoptotic population (double-labeled) 96 hours after one dose of imetelstat sodium treatment for MOLM-13 cells. Figure 17B shows the apoptotic population (double-labeled) 96 hours after one dose of imetelstat sodium treatment for AML cell line HL-60. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0020] The following detailed description of the invention is better understood when read in conjunction with the accompanying drawings. The drawings are provided to illustrate certain embodiments of the invention. However, the invention is not limited to the precise arrangements, examples and instrumentalities shown. For clarity of disclosure, and not by way of limitation, the detailed description of the invention is divided into sections that describe or illustrate particular features, embodiments or applications of the invention.
[0021] The present invention provides a method of treating hematological cancers with a combination of a telomerase inhibitor and a Bcl-2 inhibitor. A population of drug-resistant cells may result in incomplete response to treatment or relapse of the disease. The present invention provides a combination of a telomerase inhibitor and a Bcl-2 inhibitor that function synergistically to induce a level of apoptosis in AML cells that is greater than the level that either drug can induce independently. The present invention provides a method of inducing apoptosis in hematological cancer cells, comprising contacting the cells with a therapeutically effective amount of a telomerase inhibitor and a therapeutically effective amount of a Bcl-2 inhibitor. In some embodiments, the telomerase inhibitor is imetelstat. In some embodiments, the Bcl-2 inhibitor is ABT-199. In some embodiments, the hematological cancer is AML.
[0022] In certain cases, the combination provides an enhanced inhibitory effect compared to either component alone. In some cases, the combination provides a supraadditive or synergistic effect compared to the combined or additive effects of the components. Gives fruit.
[0023] In some embodiments, the method is a method of inducing apoptosis in a hematological cancer cell. The subject method may include contacting a cell with a therapeutically effective amount of a telomerase inhibitor and contacting the cell with a therapeutically effective amount of a Bcl-2 inhibitor. In certain embodiments, the telomerase inhibitor is imetelstat. In some embodiments, the telomerase inhibitor is imetelstat sodium. In some embodiments, the Bcl-2 inhibitor is ABT-199. Contacting the cell with the telomerase inhibitor may occur before, during, and / or after contacting the cell with the Bcl-2 inhibitor. Contacting the cell with the telomerase inhibitor and the Bcl-2 inhibitor may occur simultaneously or sequentially.
[0024] In certain embodiments, the telomerase inhibitor is an oligonucleotide having telomerase inhibitory activity, in particular an oligonucleotide as defined in WO 2005 / 023994 and / or WO 2014 / 088785, both of which are incorporated by reference herein.
[0025] In general, various combinations of telomerase inhibitors and Bcl-2 inhibitors may be utilized and used sequentially or simultaneously. For example, for multiple dosing, the two agents may be directly alternating or two or more doses of one agent may be replaced by a single dose of the other agent. The simultaneous administration of both agents may be alternating or otherwise interspersed with the dosing of the individual agents. In some cases, the time between doses may be from about 1-6 hours to about 6-12 hours, to about 12-24 hours, to about 1-2 days, to about 1-2 days, or even longer from the start of treatment. During the course of treatment, the need to complete the planned dosing may be reevaluated.
[0026] The term "apoptosis" refers to the process of programmed cell death, with its associated changes in cell morphology and loss of cell viability. In one embodiment, the method of inducing apoptosis provides a method of treating neoplastic disorders in a vertebrate organism.
[0027] In the context of this method, the term "induce" refers to a direct or indirect causal relationship, thus causing or leading to the induced result by the existence and / or maintenance of a particular condition.
[0028] As used herein, the term "about" when referring to a measurable value (e.g., amount, temporal duration, etc.) is meant to encompass a variation of ±20% to ±0.1% from the stated value, preferably ±20% or ±10%, more preferably ±5%, even more preferably ±1%, and even more preferably ±0.1%, as such variations are appropriate for carrying out the disclosed methods.
[0029] As used throughout, "AML" refers to acute myeloid leukemia. A. Treatment
[0030] As used herein, and as is well understood in the art, "treatment" is an approach to obtain beneficial or desired results, including clinical results.For the purposes of the present invention, beneficial or desired clinical results include, but are not limited to, alleviation or mitigation of one or more symptoms, whether detectable or undetectable, reduction in the extent of disease, a stabilized (i.e., not worsening) state of disease, prevention of disease spread, delay or slowing the progression of disease, alleviation or temporary arrest of disease state, and remission (partial or complete)."Treatment" can also mean prolonging survival time compared to expected survival without treatment.
[0031] The present disclosure provides a treatment (for hematological cancer, e.g., acute myeloid leukemia) that includes combining administration of the telomerase inhibitor imetelstat sodium with administration of the Bcl-2 inhibitor ABT-199. The subject treatment methods can be more effective and can result in a greater response to treatment in AML patients than observed with either drug alone. In one embodiment, the treatment method includes administering a telomerase inhibitor in combination with a Bcl-2 inhibitor to a subject in need of treatment for hematological cancer. In another embodiment, the hematological cancer is AML. In another embodiment, the telomerase inhibitor is imetelstat. In a particular embodiment, the telomerase inhibitor is imetelstat sodium. In another embodiment, the Bcl-2 inhibitor is ABT-199.
[0032] In some embodiments, the dose of the telomerase inhibitor administered to the subject is sufficient to treat the disease when the telomerase inhibitor is used alone. In certain embodiments, the dose of the telomerase inhibitor administered to the subject is less than sufficient to treat the disease when the telomerase inhibitor is used alone. In one embodiment, the dose of the telomerase inhibitor is reduced when used in combination with ABT-199 in treating a subject already diagnosed with AML. In some embodiments, the telomerase inhibitor is imetelstat. In some embodiments, the telomerase inhibitor is imetelstat sodium. In some embodiments, the dose of the Bcl-2 inhibitor administered to the subject is sufficient to treat the disease when the Bcl-2 inhibitor is used alone. In certain embodiments, the dose of the Bcl-2 inhibitor administered to the subject is less than sufficient to treat the disease when the Bcl-2 inhibitor is used alone. In some embodiments, the Bcl-2 inhibitor is ABT-199. In another embodiment, the dose of the Bcl-2 inhibitor is reduced when used in combination with imetelstat in treating a subject already diagnosed with AML, hi yet another embodiment, the doses of imetelstat and ABT-199 are both reduced when used in combination in treating a subject already diagnosed with AML.
[0033] In another embodiment, the length of treatment with the telomerase inhibitor is shortened when used in combination with a Bcl-2 inhibitor in the treatment of a subject with a blood cancer. In another embodiment, the length of treatment with imetelstat is shortened when used in combination with ABT-199 in the treatment of a subject with a blood cancer. In another embodiment, the length of treatment with ABT-199 is shortened when used in combination with imetelstat in the treatment of a subject diagnosed with a blood cancer. In another embodiment, the length of treatment with both imetelstat and ABT-199 is shortened when used in combination in the treatment of a subject diagnosed with a blood cancer. In some embodiments, the blood cancer is AML.
[0034] The drug combinations described herein may be administered to a subject as a composition containing both drugs or may be administered separately. The drug combinations described herein may be administered in a combined drug composition, e.g., by intravenous administration, or may be administered separately. B. Blood cancer
[0035] The methods of the present invention can be used to treat any convenient hematological malignancy. Hematological malignancies are forms of cancer that begin in the cells of blood-making tissues (e.g., bone marrow) or in the cells of the immune system. Examples of hematological cancers are acute and chronic leukemia, lymphoma, multiple myeloma, and myelodysplastic syndromes. In some cases, hematological malignancies are referred to as blood cancers. Myeloproliferative neoplasms, or MPNs, are tumors that develop in the bone marrow from neoplastic hematopoietic myeloid progenitor cells, such as precursor cells for red blood cells, platelets, and granulocytes. Myelodysplastic syndromes (MDS) are a group of conditions that include cancers of the blood and bone marrow. MDS include, but are not limited to, refractory anemia, refractory anemia with excess blasts, refractory cytopenia with polycythemia vera, and chronic myelogenous leukemia (CML). The proliferation of neoplastic precursor cells leads to the overproduction of any combination of white blood cells, red blood cells, and / or platelets, depending on the disease. These overproduced cells may be abnormal and cause further clinical complications. There are various types of chronic myeloproliferative disorders. Myeloproliferative neoplasms include essential thrombocythemia, polycythemia vera, chronic myelogenous leukemia, myelofibrosis, chronic neutrophilic leukemia, chronic eosinophilic leukemia, and acute myelogenous leukemia. Myelodysplastic syndromes (MDS) are a group of conditions that include cancers of the blood and bone marrow. MDS include, but are not limited to, refractory anemia, refractory anemia with excess blasts, refractory cytopenia with polycythemia vera, and chronic myelomonocytic leukemia (CML).
[0036] Hematological cancers of interest include, but are not limited to, AML, essential thrombocythemia, polycythemia vera, primary myelofibrosis, systemic mastocytosis, chronic myeloid leukemia, chronic neutrophilic leukemia, chronic eosinophilic leukemia, refractory anemia with ringed sideroblasts, refractory cytopenia with polycythemia vera, refractory anemia with excess blasts (type 1), refractory anemia with excess blasts (type 2), myelodysplastic syndrome (MDS) with isolated 5q deletion, unclassifiable MDS, chronic myelomonocytic leukemia (CML), atypical chronic myelogenous leukemia, juvenile myelomonocytic leukemia, unclassifiable myeloproliferative / myelodysplastic syndrome, B lymphoblastic leukemia / lymphoma, T lymphoblastic leukemia / lymphoma, These include: diffuse large B-cell lymphoma, primary central nervous system lymphoma, primary mediastinal B-cell lymphoma, Burkitt's lymphoma / leukemia, follicular lymphoma, chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma, B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma / Waldenström macroglobulinemia, mantle cell lymphoma, marginal zone lymphoma, post-transplant lymphoproliferative disorder, HIV-associated lymphoma, primary effusion lymphoma, intravascular large B-cell lymphoma, primary cutaneous B-cell lymphoma, hairy cell leukemia, monoclonal gammopathy of undetermined significance, smoldering multiple myeloma and solitary plasmacytoma (isolated bone and extramedullary).
[0037] Certain treatment regimens of the present invention are particularly suitable for treating AML. In certain embodiments of the present invention, the subject to whom treatment is administered has AML. Among AML, chemotherapy-refractory AML, for example, AML that is refractory to treatment with cytarabine in combination with daunorubicin or idarubicin, can be treated using the methods disclosed herein, for example, by administering imetelstat in combination with ABT-199. AML response to treatment is known in the art. An example of AML response evaluation is shown in Table 1. [Table 1]
[0038] The drug combinations described herein are suitable for use in the treatment of any one of the diseases or disorders described herein, including hematological cancers (including subtypes thereof). The drugs may be administered simultaneously or sequentially.
[0039] The drug combinations described herein are suitable for use in inducing apoptosis in hematological cancer cells. The drugs may be administered simultaneously or sequentially.
[0040] It will also be apparent that the compositions described herein are suitable for use in the treatment of any one of the diseases or disorders mentioned herein, including hematological cancers (including subtypes thereof). C. Subjects
[0041] The subject is a mammalian animal that needs to be treated for cancer. Generally, the subject is a human patient. In some embodiments of the present invention, the subject may be a non-human mammalian animal, such as a non-human primate, an animal model (e.g., an animal such as a mouse and a rat that is used for screening, characterizing, and evaluating pharmaceutical drugs), and other mammalian animals. As used herein, the terms patient, subject, and individual are used interchangeably. D. Anticancer drugs
[0042] The following section describes the drugs used in various embodiments of the present invention. Because these drugs are well known, only a brief discussion is given. The publications cited in this section are intended to explain the aspects of the drugs for the benefit of the physician. However, the citation of specific publications in this section or elsewhere in this disclosure is not intended to limit the present invention in any respect, including dosage, combination, indication. 1. Telomerase inhibitors
[0043] Examples of telomerase inhibitors include, but are not limited to, imetelstat, specifically imetelstat sodium. In some cases, one or more telomerase inhibitors (e.g., two or three telomerase inhibitors) may be administered to a mammal to treat a hematological malignancy.
[0044] Imetelstat sodium is the sodium salt of imetelstat, a synthetic lipid-conjugated 13-mer oligonucleotide N3'→P5'-thio-phosphoramidate. The chemical name of imetelstat sodium is DNA,d(3'-amino-3'-deoxy-P-thio)(TAGGGTTAGACAA),5'-[O-[2-hydroxy-3-(hexadecanoylamino)propyl]phosphorothioate], sodium salt (1:13) (SEQ ID NO:1). Imetelstat and imetelstat sodium may be produced, formulated, or obtained as described elsewhere (Asai et al., Cancer Res., 63(14):3931-3939 (2003); Herbert et al., Oncogene, 24:5262-5268 (2005); and Gryaznov, Chem. Biodivers., 7:477-493 (2010)).
[0045] Imetelstat and imetelstat sodium target the RNA template of telomerase and have been shown to inhibit telomerase activity and cell proliferation in various cancer cell lines and tumor xenografts in mice. Phase I studies involving patients with breast cancer, non-small cell lung cancer and other solid tumors, multiple myeloma, or chronic lymphocytic leukemia informed the pharmacokinetics and pharmacodynamics of the drug and helped establish a dose of 9.4 mg per kg of body weight (given as a 2-hour intravenous infusion). Subsequent Phase II studies involving patients with essential thrombocythemia demonstrated platelet-thinning activity concomitant with significantly reducing the burden of JAK2 V617F and CALR mutant alleles. Imetelstat sodium is typically administered intravenously. It is envisioned that other routes of administration (e.g., intrathecal administration, intratumoral injection, oral administration, and others) may also be used in the practice of the present invention. Imetelstat sodium may be administered at doses comparable to those typically utilized in clinical practice. In a preferred embodiment, imetelstat sodium is administered as described elsewhere herein.
[0046] A particular embodiment is any one of the other embodiments, wherein the imetelstat is limited to imetelstat sodium. 2. Bcl-2 inhibitor ABT-199
[0047] ABT-199 (venetoclax) represents a first-in-class, selective, platelet-sparing BCL-2 inhibitor (Figure 1B). ABT-199 exhibits subnanomolar affinity (Ki<0.010 nM) for BCL-2 and has antitumor activity against non-Hodgkin's lymphoma (NHL) and CLL in vitro. In vivo mouse xenograft studies have shown activity against intermediate-grade (Myc+) lymphomas and acute leukemias. Phase Ia trials of ABT-199 in R / R NHL used continuous daily dosing of 200–900 mg. A single dose was administered on day 7, followed by a lead-in period with stepwise titration over 2–3 weeks. Single-agent ABT-199 was also tested in a phase 2 open-label multicenter trial in patients with high-risk R / R AML and in treatment-naïve patients who were unfit for intensive chemotherapy. The trial allowed for intrapatient dose escalation, when patients received 20 mg ABT-199 on day 1 of week (Wk). Daily titration was performed with the goal of a final dose of 800 mg on day 6 and daily thereafter. Those patients without a complete response (CR) or CR with complete hematologic recovery (CRi) at the first planned evaluation (end of Wk4) were allowed to escalate to 1200 mg. The recommended phase 2 dose of ABT-199 in combination with rituximab is 400 mg daily. E. Pharmaceutical Compositions
[0048] The present invention also relates to pharmaceutical compositions comprising a telomerase inhibitor (e.g., imetelstat, particularly imetelstat sodium) and a Bcl-2 inhibitor (e.g., ABT-199). In one embodiment, the pharmaceutical composition comprises imetelstat, particularly imetelstat sodium, and ABT-199. In one embodiment, the pharmaceutical composition comprises imetelstat, particularly imetelstat sodium, and ABT-199. The drug combinations described herein may be administered to a subject as compositions comprising both drugs.
[0049] The carrier or diluent must be "acceptable" in the sense of being compatible with the other ingredients of the composition and not deleterious to the recipient thereof.
[0050] In order to facilitate administration, the drug combinations described herein may be formulated into various pharmaceutical forms for administration purposes.The drug combinations described herein may be formulated into various pharmaceutical forms for administration purposes.As suitable compositions, all of the compositions cited may be present, which are usually used for systemically administered drugs.
[0051] To prepare the pharmaceutical compositions of the present invention, combinations of effective amounts of the drugs described herein are combined in intimate admixture with a pharma- ceutically acceptable carrier, which may be in a wide variety of forms, depending on the form of preparation desired for administration. These pharmaceutical compositions are desirably in unit dosage forms suitable for oral, rectal, transdermal, parenteral injection or inhalation, among others. In some cases, administration may be by intravenous injection. For example, in preparing compositions in oral dosage form, any conventional pharmaceutical medium may be used, such as, for example, water, glycols, oils, alcohols, etc., in the case of oral liquid preparations (e.g., suspensions, syrups, elixirs, emulsions and solutions); or solid carriers, such as starches, sugars, kaolin, diluents, lubricants, binders, disintegrants, etc., in the case of powders, pills, capsules and tablets. Because of ease of administration, tablets and capsules represent the most advantageous oral dosage unit forms, when a solid pharmaceutical carrier is obviously used. For parenteral compositions, the carrier usually comprises sterile water, at least in large part, although other ingredients (e.g., ingredients to aid solubility) may be included. Injectable solutions may be prepared, for example, where the carrier comprises saline solution, glucose solution, or a mixture of saline and glucose solution. Injectable solutions may be prepared, for example, where the carrier comprises saline solution, glucose solution, or a mixture of saline and glucose solution. Injectable solutions containing the drug combinations described herein may be formulated in oil for long-term action. Suitable oils for this purpose are, for example, peanut oil, sesame oil, cottonseed oil, corn oil, soybean oil, synthetic glycol esters of long-chain fatty acids, and mixtures of these oils with other oils. Injectable suspensions may be prepared where appropriate liquid carriers, suspending agents, etc. may be used. Also included are solid form formulations that are intended to be converted to liquid form formulations immediately prior to use. In compositions suitable for subcutaneous administration, the carrier may optionally comprise a penetration enhancer and / or a suitable wetting agent, and may optionally be combined with minor amounts of suitable additives having any properties that do not have a significant deleterious effect on the skin. The additive may facilitate administration to the skin and / or aid in formulating the desired composition.These compositions may be administered in various ways, eg, as a transdermal patch, as a spot-on, as an ointment.
[0052] It is particularly advantageous to formulate the above-mentioned pharmaceutical composition in unit dosage form in order to facilitate administration and uniformity of dosage.As used herein, unit dosage form refers to a physically discrete unit suitable for single administration, each unit containing a predetermined amount of active ingredient calculated to produce a desired therapeutic effect in association with the required pharmaceutical carrier.Examples of such unit dosage forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, suppositories, injection solutions or suspensions, and the like, and segregated multiples thereof.
[0053] To enhance the solubility and / or stability of the drug in the combination described herein in the pharmaceutical composition, it may be advantageous to use α-, β- or γ-cyclodextrin or its derivatives, in particular hydroxyalkyl-substituted cyclodextrins, such as 2-hydroxypropyl-β-cyclodextrin or sulfobutyl-β-cyclodextrin. Also, co-solvents such as alcohols may enhance the solubility and / or stability of the compound according to the present invention in the pharmaceutical composition.
[0054] Depending on the mode of administration, the pharmaceutical composition preferably contains 0.05-99% by weight, more preferably 0.1-70% by weight, even more preferably 0.1-50% by weight of the drug in the combinations described herein, and 1-99.95% by weight, more preferably 30-99.9% by weight, even more preferably 50-99.9% by weight of a pharma- ceutically acceptable carrier, all percentages being based on the total weight of the composition.
[0055] The frequency of administration may be any frequency that reduces the severity of symptoms of the hematological malignancy (e.g., reduces or reverses myelofibrosis) without significant toxicity to the mammal. For example, the frequency of administration may be from about once every two months to about once a week, or from about once a month to about twice a month, or from about once every six weeks to about twice a month. The frequency of administration may remain constant or may vary over the duration of the treatment. A course of treatment with a composition comprising one or more telomerase inhibitors may include a rest period. For example, a composition comprising a telomerase inhibitor and a Bcl-2 inhibitor may be administered weekly for a period of three weeks, followed by a rest period of two weeks, and such a regimen may be repeated multiple times. When using an effective amount, various factors may affect the actual frequency of administration used for a particular application. For example, the effective amount, the duration of the treatment, the use of multiple therapeutic agents, the route of administration, and the severity of the hematological malignancy may require a higher or lower frequency of administration.
[0056] The effective duration for administering a composition comprising a telomerase inhibitor (e.g., imetelstat or imetelstat sodium) and a Bcl-2 inhibitor (e.g., ABT-199) may be any duration that reduces the severity of symptoms of a hematological malignancy (e.g., reduces or reverses myelofibrosis) without significant toxicity to the mammal. Thus, the effective duration may vary from one month to several months or years (e.g., one month to two years, one month to one year, three months to two years, three months to ten months, or three months to eighteen months). In general, the effective duration for treating a hematological malignancy may range in duration from two months to twenty months. In some cases, the effective duration may be as long as the individual mammal lives. Multiple factors may affect the actual effective duration used for a particular treatment. For example, the effective duration may vary depending on the frequency of administration, the effective amount, the use of multiple therapeutic agents, the route of administration, and the severity of the hematological malignancy.
[0057] In certain cases, the course of treatment and the severity of one or more symptoms associated with hematological malignancies may be monitored. Any method may be used to determine whether the severity of the symptoms of hematological malignancies is decreasing. For example, the severity of the symptoms of hematological malignancies (e.g., myelofibrosis) may be evaluated using biopsy techniques.
[0058] The term "pharmaceutically acceptable salt" refers to a salt that is acceptable for administration to a patient, e.g., a mammal (a salt that includes a counterion that has acceptable mammalian safety for a given dosing regimen). Such salts may be derived from pharmaceutically acceptable inorganic or organic bases and pharmaceutically acceptable inorganic or organic acids. "Pharmaceutically acceptable salt" refers to a pharmaceutically acceptable salt of a compound, which is derived from a variety of organic and inorganic counterions well known in the art, including, by way of example only, sodium, and the like, and when the molecule contains a basic functional group, an organic or inorganic acid salt (e.g., hydrochloride, etc.). Pharmaceutically acceptable salts of interest include, but are not limited to, aluminum, ammonium, arginine, barium, benzathine, calcium, choline acid, ethylenediamine, lysine, lithium, magnesium, meglumine, procaine, potassium, sodium, tromethamine, N-methylglucamine, N,N'-dibenzylethylene-diamine, chloropropane, tetrahydrofuran ... These include salts of caine, diethanolamine, ethanolamine, piperazine, zinc, diisopropylamine, diisopropylethylamine, triethylamine and triethanolamine.
[0059] The term "salt(s) thereof" refers to a compound that is formed when the proton of an acid is replaced with a cation (such as a metal cation or an organic cation). Preferably, the salt is a pharma-ceutically acceptable salt. For example, the salt of the compound of the present invention includes a salt in which the compound is protonated with an inorganic or organic acid to generate a cation with the conjugate base of the inorganic or organic acid as the anionic component of the salt. Salts of interest include, but are not limited to, aluminum, ammonium, arginine, barium, benzathine, calcium, cesium, choline acid, ethylenediamine, lithium, magnesium, meglumine, procaine, N-methylglucamine, piperazine, potassium, sodium, tromethamine, zinc, N,N'-dibenzylethylene-diamine, chloroprocaine, diethanolamine, ethanolamine, piperazine, diisopropylamine, diisopropylethylamine, triethylamine and triethanolamine salts. For any oligonucleotide structure shown herein that includes a backbone of internucleotide bonds, it is understood that such oligonucleotides may include any conventional salt form. In some embodiments, the acidic form of the internucleotide bonds is shown for simplicity. In some cases, the salts of the subject compounds are monovalent cation salts. In certain cases, the salts of the subject compounds are divalent cation salts. In some cases, the salts of the subject compounds are trivalent cation salts. "Solvate" refers to a complex formed by the combination of a solvent molecule with a molecule or ion of a solute. The solvent may be an organic compound, an inorganic compound, or a mixture of both. Some examples of solvents include, but are not limited to, methanol, N,N-dimethylformamide, tetrahydrofuran, dimethylsulfoxide, and water. When the solvent is water, the resulting solvate is a hydrate.
[0060] "Stereoisomer" and "stereoisomers" are two forms of the same molecule. Stereoisomers refer to compounds that have a bond between two atoms, but differ in the arrangement of the atoms in space. Stereoisomers include, for example, cis-trans isomers, E and Z isomers, enantiomers, and diastereomers. As any of the groups disclosed herein that contain one or more substituents, it is of course understood that such groups do not include any substitutions or substitution patterns that are sterically infeasible and / or synthetically infeasible. All stereoisomers are intended to be included within the scope of the present disclosure.
[0061] One of ordinary skill in the art will recognize that other tautomeric configurations of the groups described herein are possible. All tautomeric forms of the subject compounds are understood to be encompassed by the depicted structures, even if not specifically shown, as being one possible tautomeric configuration of the groups of the compounds.
[0062] It is intended to include pharma- ceutically acceptable salt solvates of the stereoisomeric tautomers of the subject compounds, which are intended to be included within the scope of this disclosure. F. Administration and Dosing Regimens
[0063] For the treatment of blood cancers, a telomerase inhibitor (e.g., imetelstat or imetelstat sodium) may be combined with a Bcl-2 inhibitor (e.g., ABT-199, ABT-263, and ABT-737) and administered to a subject in need of treatment. Examples of cancers treatable in this manner are acute myeloid leukemia (AML) (also called acute myelocytic leukemia), acute myeloid leukemia, acute granulocytic leukemia, or acute nonlymphocytic leukemia. In acute leukemia, the leukemia cells are immature blood cells (called blasts) that grow and divide rapidly. Without treatment, most patients with acute leukemia will only survive a few months.
[0064] The telomerase inhibitors and Bcl-2 inhibitors used in the present invention may be administered at any therapeutically effective dose (e.g., a dose comparable to a dose commonly used clinically). Specific dosing regimens (e.g., recommended effective doses) of known approved anticancer drugs are known to physicians and can be found, for example, in PHYSICIANS' DESK REFERENCE, 2003, 57th Ed., Medical Economics Company, Inc., Oradell, NJ; Goodman & Gilman's THE PHARMACOLOGICAL BASIS OF THERAPEUTICS" 2001, 10th Edition, McGraw-Hill, New York, NY; The various properties may be provided by product descriptions found in the New York Press and / or available from the Federal Drug Administration and / or described in the pharmaceutical literature.
[0065] In one embodiment, the dose of the telomerase inhibitor imetelstat sodium administered to the subject is about 1.0 mg / kg to about 13.0 mg / kg. In another embodiment, the dose of the telomerase inhibitor is about 6.5 mg / kg to about 11.7 mg / kg. In some embodiments, the dose of the telomerase inhibitor is about 6.5 mg / kg, 6.6 mg / kg, 6.7 mg / kg, 6.8 mg / kg, 6.9 mg / kg, 7 mg / kg, 7.1 mg / kg, 7.2 mg / kg, 7.3 mg / kg, 7.4 mg / kg, 7.5 mg / kg, 7.6 mg / kg, 7.7 mg / kg, 7.8 mg / kg, 7.9 mg / kg, 8 mg / kg, 8.1 mg / kg, 8.2 mg / kg, 8.3 mg / kg, 8.4 mg / kg, 8.5 mg / kg, 8.6 mg / kg, 8.7 mg / kg, 8.8 mg / kg, 8.9 mg / kg, 9 mg / kg, 9.1 mg / kg, 9.2 mg / kg, 9.3 mg / kg, 9.4 mg / kg, 9.5 mg / kg, 9.6 mg / kg, 9.7 mg / kg, 9.8 mg / kg, 9.9mg / kg, 10mg / kg, 10.1mg / kg, 10.2mg / kg, 10.3mg / kg, 10.4mg / kg, 10.5mg / kg, 10.6mg / kg, 10.7m g / kg, 10.8mg / kg, 10.9mg / kg, 11mg / kg, 11.1mg / kg, 11.2mg / kg, 11.3mg / kg, 11.4mg / kg, 11.5mg / kg , 11.6mg / kg, 11.7mg / kg, 11.8mg / kg, 11.9mg / kg, 12mg / kg, 12.1mg / kg, 12.2mg / kg, 12.3mg / kg, 12.4mg / kg, 12.5mg / kg, 12.6mg / kg, 12.7mg / kg, 12.8mg / kg, 12.9mg / kg or 13mg / kg.
[0066] In some embodiments, the effective amount of the telomerase inhibitor administered to an individual comprises at least about 1 mg / kg, 2.5 mg / kg, 3.5 mg / kg, 5 mg / kg, 6.5 mg / kg, 7.5 mg / kg, 9.4 mg / kg, 10 mg / kg, 15 mg / kg, or 20 mg / kg. In various embodiments, the effective amount of the telomerase inhibitor administered to an individual comprises less than about 350 mg / kg, 300 mg / kg, 250 mg / kg, 200 mg / kg, 150 mg / kg, 100 mg / kg, 50 mg / kg, 30 mg / kg, 25 mg / kg, 20 mg / kg, 10 mg / kg, 7.5 mg / kg, 6.5 mg / kg, 5 mg / kg, 3.5 mg / kg, 2.5 mg / kg, 1 mg / kg, or 0.5 mg / kg of the telomerase inhibitor.
[0067] Exemplary dosing frequencies of pharmaceutical compositions (e.g., pharmaceutical compositions comprising a telomerase inhibitor and / or a pharmaceutical composition comprising a Bcl-2 inhibitor) include, but are not limited to, daily; every other day; twice a week; three times a week; weekly without interruption; weekly for three out of four weeks; once every three weeks; once every two weeks; weekly for two out of three weeks. In some embodiments, the pharmaceutical composition is administered approximately once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, or once every eight weeks. In some embodiments, the composition is administered approximately at least once, twice, three times, four times, five times, six times, or seven times a week (i.e., daily), or three times daily, twice daily. In some embodiments, the interval between each administration is less than about 6 months, 3 months, 1 month, 20 days, 15 days, 12 days, 10 days, 9 days, 8 days, 7 days, 6 days, 5 days, 4 days, 3 days, 2 days, or 1 day. In some embodiments, the interval between each administration is more than about 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 8 months, or 12 months. In some embodiments, there is no break in the dosing schedule. In some embodiments, the interval between each administration is not more than about 1 week.
[0068] The telomerase inhibitor, e.g., imetelstat or imetelstat sodium, may be administered using any suitable method. For example, the telomerase inhibitor, e.g., imetelstat or imetelstat sodium, may be administered intravenously over a period of time (e.g., 1 hour, 2 hours, 3 hours, 4 hours, or 5 hours) once every 4 weeks. In one embodiment, imetelstat is administered intravenously at 7-10 mg / kg for a period of about 2 hours once every week. In another embodiment, imetelstat is administered intravenously at 2.5-7 mg / kg for a period of about 2 hours once every 3 weeks. In yet another embodiment, imetelstat is administered intravenously at 0.5-5 mg / kg for a period of about 2 hours once every 4 weeks. In another embodiment, imetelstat is administered intravenously at 2.5-10 mg / kg for a period of about 2 hours once every 3 weeks. In yet another embodiment, imetelstat is administered intravenously at 0.5-9.4 mg / kg over a period of about 2 hours once every 4 weeks.
[0069] In such cases, when treating with the Bcl-2 inhibitor ABT-199, the dose of ABT-199 may be about 400 mg PO qDay or less. For example, a human identified as having a hematological malignancy may be treated with ABT-199 at a dose of (a) 20 mg PO qDay, (b) 50 mg PO qDay, (c) 100 mg PO qDay, (d) 200 mg PO qDay, or (e) 400 mg PO qDay. In another embodiment, ABT-199 is administered according to a schedule of weekly titrations over five weeks to a recommended daily dose of 400 mg, starting with 20 mg PO qDay in week 1, 50 mg PO qDay in week 2, 100 mg PO qDay in week 3, 200 mg PO qDay in week 4, and 400 mg in weeks 5 and beyond. In another embodiment, ABT-199 is administered at 400 mg PO qDay. In another embodiment, dosing is continued until disease progression or unacceptable toxicity.
[0070] It will be understood that cancer treatments sometimes include multiple "rounds" or "cycles" of drug administration, with each cycle including one or more drug administrations according to a particular schedule (e.g., 3 consecutive days every 3 weeks, once a week, etc.). For example, an anti-cancer drug may be administered for 1-8 cycles, or even longer. When more than one drug (e.g., two drugs) are administered to a subject, each may be administered according to its own schedule (e.g., weekly, once every 3 weeks, etc.). It will be apparent that drug administration, even when administered at different cycles, can be coordinated such that both drugs are administered on the same day at least some of the time, or alternatively, the drugs are administered on consecutive days at least some of the time.
[0071] In treatment regimens in which a telomerase inhibitor (e.g., imetelstat or imetelstat sodium) and a Bcl-2 inhibitor (e.g., ABT-199 or Veneteclax) are administered in combination, they may be administered in any order. In certain embodiments, the telomerase inhibitor is administered one day before, one day after, or on the same day as the administration of the Bcl-2 inhibitor. It is understood that other schedules may be used as determined by the physician.
[0072] As is understood in the art, treatment with cancer therapeutic agents may be temporarily interrupted when toxicity is observed and then resumed for the convenience of the patient without departing from the scope of the invention. G. Combination Administration
[0073] When drugs are administered as part of the same course of treatment, two or three drugs are administered to a subject in "combination." Course of treatment refers to the administration of a combination of drugs that medical professionals believe act together additively, complementary, synergistically, or in other ways to provide more desirable results than would be expected for administration of a single drug. Course of treatment may last for one or several days, but more often lasts for several weeks.
[0074] Thus, an example of combined dosing is imetelstat administered once every 28 days for 1-4 cycles starting on day 1, and ABT-199 administered once every 7 days for 4 cycles starting on day 1. In one embodiment, administration of ABT-199 begins on day 1, day -1, or day 2, or another day within the cycle. In one embodiment, an example of combined dosing is imetelstat administered once every 28 days for 1-4 cycles starting on day 1, and ABT-199 administered once daily for 28 days starting on day 1 for 1-4 cycles.
[0075] When two drugs are administered in combination, various schedules can be used. In some cases, for example and without limitation, drug 1 is administered first before drug 2 is administered, and drug 1 treatment is continued throughout the course of drug 2 administration. Or drug 1 is administered after drug 2 treatment is started or completed. Or drug 1 is administered first at the same time as the start of other cancer treatment. When used in this context, "concurrently" means that the two drugs are administered on the same day or on consecutive days.
[0076] In principle, certain drugs may be formulated together, but generally, certain drugs are administered in separate compositions. Likewise, certain drugs may be administered simultaneously, but more often (especially in the case of drugs administered by injection), the drugs are administered at different times on the same day, or on consecutive days, or according to different schedules.
[0077] The present invention also relates to a combination comprising a telomerase inhibitor and a Bcl-2 inhibitor. In particular, the telomerase inhibitor is imetelstat and the Bcl-2 inhibitor is ABT-199. In particular, the telomerase inhibitor is imetelstat sodium and the Bcl-2 inhibitor is ABT-199.
[0078] The present invention also relates to a combination comprising a telomerase inhibitor and a Bcl-2 inhibitor for use as a medicament. In particular, the telomerase inhibitor is imetelstat and the Bcl-2 inhibitor is ABT-199. In particular, the telomerase inhibitor is imetelstat sodium and the Bcl-2 inhibitor is ABT-199. H. Diagnosis
[0079] For the diagnosis of AML, blood and bone marrow smears are examined morphologically using May-Gruenwald-Giemsa or Wright-Giemsa staining. It is recommended that at least 200 leukocytes be counted in blood smears and 500 nucleated cells in bone marrow smears, the latter including spicules. For the diagnosis of AML, bone marrow or blood blast counts of 20% or more are required, except in AML with t(15;17), t(8;21), inv(16), or t(16;16) and in some cases of erythroleukemia. Myeloblasts, monoblasts, and megakaryoblasts are included in the blast count. In AML with monocytic or myelomonocytic differentiation, monoblasts and promonocytes are counted as blast equivalents, although they are not abnormal monocytes. Erythroblasts are not counted as blasts, except in rare cases of pure erythroleukemia. I. Kit
[0080] The present invention also relates to a kit comprising a telomerase inhibitor and a Bcl-2 inhibitor. A kit comprising a telomerase inhibitor and a Bcl-2 inhibitor for use in treating hematological cancer is also provided. Such treatment may, in some cases, comprise administering a Bcl-2 inhibitor to a subject before, after, or simultaneously with administering a telomerase inhibitor. In some cases, the telomerase inhibitor is imetelstat.
[0081] In a related aspect, the present invention provides a kit comprising a telomerase inhibitor in a dose amount effective to inhibit the proliferation of cancer cells in a subject. The kit may include a package insert containing instructions for administering the telomerase inhibitor. The package insert may provide a user with a set of instructions for using the inhibitor in combination with a Bcl-2 inhibitor. In some cases, the Bcl-2 inhibitor is ABT-199.
[0082] In some cases, the set of instructions for combination therapy may recommend (i) a lower dose of the telomerase inhibitor when used in combination with the Bcl-2 inhibitor, (ii) a lower dose of the Bcl-2 inhibitor when used in combination with the telomerase inhibitor, and / or (iii) a different dosing regimen than is normally recommended for one or both inhibitors.
[0083] In this paragraph it is apparent that in some cases above the telomerase inhibitor is imetelstat, in some cases the telomerase inhibitor is imetelstat sodium, and in some cases the Bcl-2 inhibitor is ABT-199. J. Exemplary Embodiments
[0084] An exemplary embodiment of the present invention is a method of treatment comprising administering a combination of a telomerase inhibitor and a Bcl-2 inhibitor to a subject in need of treatment for hematological cancer. In a particular embodiment, the telomerase inhibitor is imetelstat. In an alternative embodiment, the Bcl-2 inhibitor is ABT-199, ABT-263 or ABT-737. In yet another embodiment, the Bcl-2 inhibitor is ABT-199. In one embodiment, the telomerase inhibitor is imetelstat and the Bcl-2 inhibitor is ABT-199.
[0085] Hematological malignancies include AML, essential thrombocythemia, polycythemia vera, primary myelofibrosis, systemic mastocytosis, chronic myeloid leukemia, chronic neutrophilic leukemia, chronic eosinophilic leukemia, refractory anemia with ringed sideroblasts, refractory cytopenia with polycythemia dysplasia, refractory anemia with excess blasts (type 1), refractory anemia with excess blasts (type 2), myelodysplastic syndrome (MDS) with isolated deletion of the long arm of chromosome 5 (5q), unclassifiable MDS, chronic myelomonocytic leukemia (CML), atypical chronic myelogenous leukemia, juvenile myelomonocytic leukemia, unclassifiable myeloproliferative / myelodysplastic syndrome, B lymphoblastic leukemia / lymphoma, T lymphoblastic leukemia / lymphoma, diffuse large cell myelodysplastic syndrome (LDS), and myelodysplastic syndrome (MDS). The cancer may be follicular B-cell lymphoma, primary central nervous system lymphoma, primary mediastinal B-cell lymphoma, Burkitt's lymphoma / leukemia, follicular lymphoma, chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma, B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma / Waldenström's macroglobulinemia, mantle cell lymphoma, marginal zone lymphoma, post-transplant lymphoproliferative disorder, HIV-associated lymphoma, primary effusion lymphoma, intravascular large B-cell lymphoma, primary cutaneous B-cell lymphoma, hairy cell leukemia, monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and solitary plasmacytoma (solitary bone and extramedullary). In one embodiment, the hematological cancer is AML.
[0086] In certain embodiments, the telomerase inhibitor imetelstat is administered in 1, 2, 3, 4, 5, 6, 7, 8, or more than 8 dosing cycles, each cycle comprising: (a) about 7-10 mg / kg of imetelstat administered intravenously once every 4 weeks; (b) about 7-10 mg / kg of imetelstat administered intravenously once every week for 4 weeks; (c) about 2.5-7 mg / kg of imetelstat administered intravenously once every 3 weeks; or (d) about 0.5-9.4 mg / kg of imetelstat administered intravenously once every 4 weeks. The imetelstat may be imetelstat sodium.
[0087] In certain embodiments, ABT-199 is administered (a) at a dose of about 50-400 mg of ABT-199 daily; (b) at a dose of about 2 mg of ABT-199 on day 1, increasing daily thereafter to a final dose of about 800 mg on day 6, and at that final dose daily thereafter; or (c) at a dose of 25 mg of ABT-199 on day 1, increasing daily thereafter to a final dose of about 400 mg on day 5, and at that final dose daily thereafter. Administration of ABT-199 may be one day prior to, one day after, or on the same day as administration of the telomerase inhibitor.
[0088] Another embodiment of the present invention is a method of inducing apoptosis in a hematological cancer cell, comprising contacting the cell with a therapeutically effective amount of a telomerase inhibitor and contacting the cell with a therapeutically effective amount of a Bcl-2 inhibitor. The method may be performed in vitro or in vivo. In one embodiment, the telomerase inhibitor is imetelstat. In another embodiment, the imetelstat is imetelstat sodium. In this method, the Bcl-2 inhibitor is ABT-199. In certain embodiments, the hematological cancer cells are selected from the group consisting of acute myeloid leukemia (AML), essential thrombocythemia, polycythemia vera, primary myelofibrosis, systemic mastocytosis, chronic myeloid leukemia, chronic neutrophilic leukemia, chronic eosinophilic leukemia, refractory anemia with ringed sideroblasts, refractory cytopenia with polycythemia dysplasia, refractory anemia with excess blasts (type 1), refractory anemia with excess blasts (type 2), myelodysplastic syndrome (MDS) with isolated 5q deletion, unclassifiable MDS, chronic myelomonocytic leukemia (CML), atypical chronic myeloid leukemia, juvenile myelomonocytic leukemia, unclassifiable myeloproliferative / myelodysplastic syndrome, B lymphoblastic leukemia / lymphoma, T lymphoblastic leukemia / lymphoma, and The cells may be from the following types of cancer: diffuse large B-cell lymphoma, primary central nervous system lymphoma, primary mediastinal B-cell lymphoma, Burkitt's lymphoma / leukemia, follicular lymphoma, chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma, B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma / Waldenström's macroglobulinemia, mantle cell lymphoma, marginal zone lymphoma, post-transplant lymphoproliferative disorder, HIV-associated lymphoma, primary effusion lymphoma, intravascular large B-cell lymphoma, primary cutaneous B-cell lymphoma, hairy cell leukemia, monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and solitary plasmacytoma (solitary bone and extramedullary). In one embodiment, the blood cancer cells are acute myeloid leukemia (AML) cells.
[0089] The present invention also provides a kit for combination therapy. Thus, one embodiment of the present invention is a kit comprising: (a) a telomerase inhibitor in a dose amount effective to induce apoptosis in blood cancer cells when administered; and (b) a Bcl-2 inhibitor in a dose amount effective to induce apoptosis in blood cancer cells when administered. In one embodiment of the kit, the telomerase inhibitor is imetelstat and the Bcl-2 inhibitor is ABT-199.
[0090] One embodiment of the present invention is a pharmaceutical composition comprising a telomerase inhibitor (e.g., imetelstat / imetelstat sodium) and a BCL-2 inhibitor (e.g., ABT-199) for use in the treatment of hematological cancers. In one embodiment, the pharmaceutical composition comprises imetelstat / imetelstat sodium and ABT-199.
[0091] Another embodiment of the invention is a telomerase inhibitor for use in a method of treating a hematological cancer, the method comprising administering to a subject in need of treatment a telomerase inhibitor in combination with a Bcl-2 inhibitor. Yet another embodiment of the invention is a Bcl-2 inhibitor for use in a method of treating a hematological cancer, the method comprising administering to a subject in need of treatment a Bcl-2 inhibitor in combination with a telomerase inhibitor. An alternative embodiment of the invention is a combination of a telomerase inhibitor and a Bcl-2 inhibitor for use in a method of treating a hematological cancer, the method comprising administering to a subject in need of treatment the combination. In these embodiments, the combination of the telomerase inhibitor and the Bcl-2 inhibitor induces apoptosis of hematological cancer cells. In these embodiments, the telomerase inhibitor may be imetelstat. In one embodiment, the imetelstat is imetelstat sodium. Also, in these embodiments, the Bcl-2 inhibitor may be ABT-199. Imetelstat may be for administration in 1, 2, 3, 4, 5, 6, 7, 8, or more than 8 dosing cycles, each cycle comprising: (a) about 7-10 mg / kg of imetelstat administered intravenously once every 4 weeks; (b) about 7-10 mg / kg of imetelstat administered intravenously once every week for about 4 weeks; or (c) about 2.5-7 mg / kg of imetelstat administered intravenously once every 3 weeks; or (d) about 0.5-9.4 mg / kg of imetelstat administered intravenously once every 4 weeks. ABT-199 may be for administration: (a) at a dose of about 50-400 mg of ABT-199 daily; (b) at a dose of about 2 mg of ABT-199 on day 1, increasing daily thereafter to a final dose of about 800 mg on day 6, and at that final dose daily thereafter; or (c) at a dose of about 25 mg of ABT-199 on day 1, increasing daily thereafter to a final dose of 400 mg on day 5, and at that final dose daily thereafter. In certain embodiments, administration of ABT-199 is one day prior to, one day after, or on the same day as administration of the telomerase inhibitor.
[0092] In embodiments of the telomerase inhibitor, Bcl-2 inhibitor, or combination, the hematological cancer is acute myeloid leukemia (AML), essential thrombocythemia, polycythemia vera, primary myelofibrosis, systemic mastocytosis, chronic myeloid leukemia, chronic neutrophilic leukemia, chronic eosinophilic leukemia, refractory anemia with ringed sideroblasts, refractory cytopenia with polycythemia dysplasia, refractory anemia with excess blasts (type 1), refractory anemia with excess blasts (type 2), myelodysplastic syndrome (MDS) with isolated 5q deletion, unclassifiable MDS, chronic myelomonocytic leukemia (CML), atypical chronic myeloid leukemia, juvenile myelomonocytic leukemia, unclassifiable myeloproliferative / myelodysplastic syndrome, B-lymphoblastic leukemia / lymphoblastic leukemia, The hematological cancer may be, for example, T-lymphoblastic leukemia / lymphoma, diffuse large B-cell lymphoma, primary central nervous system lymphoma, primary mediastinal B-cell lymphoma, Burkitt's lymphoma / leukemia, follicular lymphoma, chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma, B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma / Waldenström macroglobulinemia, mantle cell lymphoma, marginal zone lymphoma, post-transplant lymphoproliferative disorder, HIV-associated lymphoma, primary effusion lymphoma, intravascular large B-cell lymphoma, primary cutaneous B-cell lymphoma, hairy cell leukemia, monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and solitary plasmacytoma (solitary bone and extramedullary). In one embodiment, the hematological cancer is acute myeloid leukemia (AML).
[0093] An alternative embodiment of the present invention is an in vitro method of inducing apoptosis in hematological cancer cells, comprising contacting the cells with a therapeutically effective amount of a telomerase inhibitor and contacting the cells with a therapeutically effective amount of a Bcl-2 inhibitor. In one embodiment, the telomerase inhibitor is imetelstat. The imetelstat may be imetelstat sodium. The Bcl-2 inhibitor may be ABT-199.
[0094] In certain embodiments of this in vitro method, the hematological cancer cells are selected from the group consisting of acute myeloid leukemia (AML), essential thrombocythemia, polycythemia vera, primary myelofibrosis, systemic mastocytosis, chronic myeloid leukemia, chronic neutrophilic leukemia, chronic eosinophilic leukemia, refractory anemia with ringed sideroblasts, refractory cytopenia with polycythemia dysplasia, refractory anemia with excess blasts (type 1), refractory anemia with excess blasts (type 2), myelodysplastic syndrome (MDS) with isolated 5q deletion, unclassifiable MDS, chronic myelomonocytic leukemia (CML), atypical chronic myeloid leukemia, juvenile myelomonocytic leukemia, unclassifiable myeloproliferative / myelodysplastic syndrome, B lymphoblastic leukemia / lymphoma, T lymphoblastic leukemia / lymphoma, and / or myelodysplastic syndrome. The cells are derived from the following types of cancer: lymphoma, diffuse large B-cell lymphoma, primary central nervous system lymphoma, primary mediastinal B-cell lymphoma, Burkitt's lymphoma / leukemia, follicular lymphoma, chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma, B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma / Waldenström macroglobulinemia, mantle cell lymphoma, marginal zone lymphoma, post-transplant lymphoproliferative disorder, HIV-associated lymphoma, primary effusion lymphoma, intravascular large B-cell lymphoma, primary cutaneous B-cell lymphoma, hairy cell leukemia, monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and solitary plasmacytoma (solitary bone and extramedullary). In one embodiment of this in vitro method, the blood cancer cells are acute myeloid leukemia (AML) cells.
[0095] Yet another embodiment of the present invention is a combination comprising a telomerase inhibitor and a Bcl-2 inhibitor. In one embodiment, the telomerase inhibitor is imetelstat and the Bcl-2 inhibitor is ABT-199. In another embodiment, the telomerase inhibitor is imetelstat sodium and the Bcl-2 inhibitor is ABT-199. This combination may be for use as a medicine.
[0096] Another embodiment of the present invention is the use of imetelstat or imetelstat sodium to treat hematological cancers in patients undergoing BCL inhibitor therapy. An alternative embodiment is the use of ABT-199 to treat hematological cancers in patients undergoing telomerase inhibitor therapy. Yet another embodiment of the present invention is imetelstat sodium for use in a method for treating acute myeloid leukemia (AML), the method comprising administering imetelstat sodium and ABT-199 in combination to a subject in need of treatment. A further embodiment is ABT-199 for use in a method for treating acute myeloid leukemia (AML), the method comprising administering imetelstat sodium and ABT-199 in combination to a subject in need of treatment. A further embodiment is a combination comprising imetelstat sodium and ABT-199 for use in a method for treating acute myeloid leukemia (AML), the method comprising administering the combination to a subject in need of treatment. Where applicable, in these embodiments, the imetelstat sodium is for administration for 1, 2, 3, 4, 5, 6, 7, 8, or more than 8 dosing cycles, each cycle comprising: (a) about 7-10 mg / kg of imetelstat sodium administered intravenously once every 4 weeks; (b) about 7-10 mg / kg of imetelstat sodium administered intravenously once every week for 4 weeks; or (c) about 2.5-7 mg / kg of imetelstat sodium administered intravenously once every 3 weeks; or (d) about 0.5-9.4 mg / kg of imetelstat sodium administered intravenously once every 4 weeks. Further, in these embodiments, ABT-199 may be for administration: (a) about 50-400 mg of ABT-199 daily; (b) at a dose of about 2 mg of ABT-199 on day 1, increasing daily thereafter to a final dose of 800 mg on day 6, and at that final dose every day thereafter; or (c) at a dose of about 25 mg of ABT-199 on day 1, increasing daily thereafter to a final dose of 400 mg on day 5, and at that final dose every day thereafter. In certain of these embodiments, administration of ABT-199 is one day prior to, one day after, or on the same day as administration of imetelstat sodium.
[0097] Yet another embodiment of the present invention is an in vitro method of inducing apoptosis in acute myeloid leukemia (AML) cells comprising contacting the cells with a therapeutically effective amount of imetelstat sodium and contacting the cells with a therapeutically effective amount of ABT-199.
[0098] In all of the above embodiments, the telomerase inhibitor may be imetelstat and the Bcl-2 inhibitor may be ABT-199. More particularly, in all of the above embodiments, the telomerase inhibitor may be imetelstat sodium and the Bcl-2 inhibitor may be ABT-199.
[0099] The present invention is further illustrated, but not limited, by the following examples. EXAMPLES
[0100] Example 1: The telomerase inhibitor imetelstat sodium in combination with the BCL-2 inhibitor venetoclax enhances apoptosis in AML cell lines in vitro. AML tumor cells KG-1 (ATCC no. CCL-246) and MOLM-13 (DSMZ no. ACC554) were plated in 96-well polystyrene U-bottom tissue culture plates (Corning catalog no. 353777) at a density of approximately 20,000 cells / well in RPMI-1640 (ThermoFisher catalog no. 11875-085) supplemented with 10% fetal bovine serum (ThermoFisher catalog no. 16140-089) and 1% penicillin / streptomycin antibiotic cocktail (ThermoFisher catalog no. 15140-122) and grown in a humidified 5% CO2 atmosphere in a 37°C incubator. Cells were immediately treated with imetelstat sodium (Janssen Biotech, Inc.) prepared in RPMI-1640 supplemented with 10% fetal bovine serum and / or ABT-199 (Selleckchem catalog no. S8048) prepared as a 1000x stock in DMSO and diluted 1:100 in phosphate-buffered saline (PBS, vehicle; ThermoFisher catalog no. 20012-027). In a 96-hour experiment, a second dose of compound was applied at 48 hours without adding fresh medium, as ABT-199 and imetelstat sodium both have in-vitro half-lives of less than 48 hours (Shammas et al., Leukemia, 22(7):1410-1418 (2008)). Imetelstat sodium was tested from 0 to 50 μM and ABT-199 was tested from 0 to 500 nM. Control non-complementary oligonucleotides and mismatch oligonucleotides (US No. 7,998,938) was used at the same concentrations as imetelstat sodium to show that the effect was specific to the combination of imetelstat sodium and ABT-199. [Table 2]
[0101] At 48 and 96 hours, cells were assayed for healthy, early apoptotic and proapoptotic populations using an Annexin V (an internal cell membrane stain) and Propidium Iodide (PI, a dye that binds DNA) flow cytometry assay kit (BioLegend catalog 640914). Annexin V detects externalization of phosphatidylserine in apoptotic cells using recombinant Annexin V conjugated to a green fluorescent FITC dye and Propidium Iodide (PI) detects dead cells. Propidium Iodide stains necrotic cells with red fluorescence. After treatment with both probes, early apoptotic cells show green fluorescence, apoptotic (dead) cells show red and green fluorescence, and live cells show little or no fluorescence. Briefly, cells were pelleted and washed twice with PBS before being suspended in Annexin V binding buffer containing anti-Annexin V-FITC and Propidium Iodide in a 1:2 ratio according to the manufacturer's suggested protocol. Cells were stained for 30 min at 4°C in the dark, then washed three times with PBS and suspended in FACs Stain Buffer (BD Cat 554657) before examination on a BD FACs Canto flow cytometer for forward scatter, side scatter, FITC and PE channels. Cell populations were analyzed using Cytobank software and compared to untreated (no imetelstat sodium or ABT-199) conditions to establish gating boundaries for live cells (not stained in either channel, i.e. double negative population). For all experiments, dot plots of flow cytometry data show four quadrants with the percentage of live cells in the lower left quadrant, the percentage of early apoptotic cells (Annexin V+ / PI-) in the upper left quadrant and the percentage of apoptotic (dead) cells (double labeled Annexin V+ / PI+) in the upper right quadrant. Apoptotic cells (double negative) were analyzed using the Cytobank software. The proportion of 100% β-labeled (100% β-labeled) was used to calculate the combined effect using both the Highest Single Agent (HSA) and Bliss additive models (J Tang et al. Frontiers in Pharmacology. 2015;6(181)).
[0102] Using the HSA model, for each dose in the combination, the cytotoxic effect of the combined state (“C”) was compared with the effect produced by each single-agent control (“A” or “B”). Excess over HSA = C - A (when A > B) or C - B (when A < B).
[0103] The Bliss model makes a similar comparison, but instead of the maximum effect of a single agent, the Bliss model subtracts the product from a combination of values equal to the sum of each single agent. Excess over Bliss = C - [(A + B) - (A * B)].
[0104] These models can show additivity or weak synergism in a combination. Results of AML cell line treatment
[0105] Dot plots of flow cytometry data of KG-1 cells after 48-hour treatment with imetelstat sodium and / or ABT-199 are shown in Figure 1A, and graphs of apoptotic cells (double-labeled)% versus ABT-199 concentration at various imetelstat sodium concentrations are shown in Figure 1B. KG-1 shows low sensitivity to ABT-199 after 48 hours (about 9% and about 14% at 100 nM and 500 nM, respectively) and minimal sensitivity to imetelstat sodium. However, when treatment with 50 μM of imetelstat sodium is combined with 100 nM or 500 nM of ABT-199, a greater effect on cell death is observed (about 27% at 100 nM and about 50% at 500 nM). Tables 3 and 4 show the calculation results of the combined effect using the HSA model or the BLISS model when KG-1 cells are treated for 48 hours. Negative values do not indicate antagonism in these models but simply indicate no interaction.
Table 3
Table 4
[0106] Dot plots of flow cytometry data for KG-1 cells after 96 h treatment with imetelstat sodium and / or ABT-199 are shown in Figure 2A, and a graph of % apoptotic cells (double-labeled) versus ABT-199 concentration at various imetelstat sodium concentrations is shown in Figure 2B. KG-1 exhibit low sensitivity to ABT-199 after 96 h (~6% and ~10% at 100 nM and 500 nM, respectively), with some sensitivity to imetelstat sodium also observed (5%, 9% and 16% at 10 μM, 20 μM and 50 μM, respectively). However, when 25 μM or 50 μM imetelstat sodium treatment is combined with 20-500 nM ABT-199, an even greater effect on cell death is observed at all concentrations. Tables 5 and 6 show the calculated combination effects using the HSA or BLISS models when KG-1 cells were treated for 96 hours. [Table 5] [Table 6]
[0107] Dot plots of flow cytometry data for KG-1 cells after treatment with mismatched or non-complementary oligonucleotides and ABT-199 for 48 hours (FIG. 3A) or 96 hours (FIG. 4A). Graphs of % apoptotic cells (double labeled) versus ABT-199 concentration at various oligonucleotide concentrations are shown for 48 hours (FIG. 3B) or 96 hours (FIG. 4B). Excess over the highest single-agent model (Tables 7 and 8) and excess over the Bliss model (Tables 9 and 10) confirm the absence of any effect with oligonucleotide controls. Negative values do not indicate antagonism in these models, but simply the absence of interaction. [Table 7] [Table 8] [Table 9] [Table 10]
[0108] Dot plots of flow cytometry data for MOLM-13 cells after 48 h of treatment with imetelstat sodium and / or ABT-199 are shown in Figure 5A, and a graph of % apoptotic cells (double-labeled) versus ABT-199 concentration at various imetelstat sodium concentrations is shown in Figure 5B. MOLM-13 showed some sensitivity to ABT-199 after 48 h (~19% and ~30% at 100 nM and 500 nM, respectively) and some sensitivity to imetelstat sodium (21.5% at 50 μM). However, when 25 μM imetelstat sodium was combined with ABT-199, an even greater effect on cell death was observed (~32% and ~72% at 100 nM and 500 nM, respectively). The greatest effect on cell death was observed with 50 μM imetelstat sodium in combination with 100 nM (62%) and 500 nM (88%) ABT-199. Surprisingly, when combined with 50 μM imetelstat sodium, ABT-199 had an effect on cell killing at concentrations as low as 5 nM and 20 nM. Tables 11 and 12 show the calculated combination effect using the HSA model or the BLISS model when treating MOLM-13 cells for 48 hours. [Table 11] [Table 12]
[0109] Dot plots of flow cytometry data for MOLM-13 cells after 96 h treatment with imetelstat sodium and / or ABT-199 are shown in Figure 6A, and a graph of % apoptotic cells (double-labeled) versus ABT-199 concentration at various imetelstat sodium concentrations is shown in Figure 6B. MOLM-13 showed sensitivity to ABT-199 after 96 h (>30% cell death at 5, 20, 100, and 500 nM) and to imetelstat sodium (>30% at 10, 25, and 50 μM). All concentrations of combined ABT-199 and imetelstat sodium treatments enhanced cell killing. Greater than 90% cell death was observed at the lowest concentration of imetelstat sodium (10 μM) when combined with the highest concentration of ABT-199 (500 nM). Greater than 90% cell death was observed when ABT-199 was combined at concentrations of 100 nM and 500 nM. At the highest concentration of imetelstat sodium (50 μM), nearly complete cell death was observed at ABT-199 concentrations of 5, 10, 20, 100, and 500 nM. Tables 13 and 14 show the calculated combination effects using the HSA or BLISS models when treating MOLM-13 cells for 96 hours. [Table 13] [Table 14]
[0110] Dot plots of flow cytometry data for MOLM-13 cells after treatment with mismatched or non-complementary oligonucleotides and ABT-199 for 48 hours (FIG. 7A) or 96 hours (FIG. 8A). Graphs of % apoptotic cells (double labeled) versus ABT-199 concentration at various oligonucleotide concentrations are shown for 48 hours (FIG. 7B) or 96 hours (FIG. 8B). Excess over the highest single-agent model (Tables 15 and 17) and excess over the Bliss model (Tables 16 and 18) confirm that there is no effect with the oligonucleotide control. Negative values do not indicate antagonism in these models, but simply a lack of interaction. [Table 15] [Table 16] [Table 17] [Table 18] Example 2: Examination of the mechanism of interaction of imetelstat sodium with ABT-199 in treated cells.
[0111] Mechanistically, imetelstat sodium functions primarily by inhibiting the active site of the telomerase enzyme complex. When the active site is inhibited, the telomere ends where the enzyme acts are therefore not elongated. Rapid and repeated cell division of tumor cells predisposes them to progressive telomere shortening over time. When the telomere regeneration process is blocked, cells progressively approach crisis and ultimately undergo apoptosis (Bruedigam et al, Cell Stem Cell, 15:775-790 (2014)).
[0112] Bcl-2 and its related family members play a role in delivering anti-apoptotic signals to tumor cells. Bcl-2 acts by inhibiting Bax, a key mediator in signaling the release of apoptotic factors that lead to normal programmed cell death. Under these signals, Bax translocates to mitochondria, initiates cytochrome c and other apoptotic factors, activates the caspase cascade, and completes cell death via the intrinsic (i.e., non-receptor mediated-TRAIL, TNFa, etc.) pathway. The presence of Bcl-2 results in the disruption of these signals, as Bcl-2 can directly inhibit Bax. Without Bax, the apoptotic factors are not released and the cell is free of the apoptotic signals.
[0113] These two pathways come together as the main protein component of telomerase, hTERT, also plays a supporting role in the intrinsic apoptotic pathway intersecting with Bcl-2. In addition to this, Bcl-2 is known to also enhance hTERT expression and subsequent telomerase activity, further reducing apoptosis in tumor cells. It has been shown that hTERT can interfere with Bax before it reaches the mitochondria and initiates the cascade of apoptotic signals. In addition to this, within the mitochondria, hTERT can enhance the inhibitory effect of Bcl-2 on Bax. To further elucidate the mechanism of interaction between imetelstat sodium and ABT-199 in treated cells, hTERT expression was measured by assessing the transcriptional level using RT-qPCR, and telomerase activity was assessed using proteins from lysed cells in a PCR-based TRAP assay. hTERT transcript levels
[0114] Samples from the cell experiments (and single drug controls) were collected for molecular analysis to evaluate the effects of the combinations contributing to a possible mechanism of action. AML cells were grown for 48 and 96 h as in the previous experiments in batches of 8 million cells in 8 mL of medium dosed with either 50 μM imetelstat sodium, 20 nM ABT-199, 50 μM imetelstat sodium and 20 nM ABT-199 or no drug in Falcon T25 flasks (Corning catalogue 353135), and then collected as cell pellets for lysis and either nucleic acid or protein extraction. Nucleic acids were purified by first lysing the cells with 350 μL of RLT buffer (Qiagen catalogue no. 1030963) supplemented with 2-mercaptoethanol (Sigma catalogue no. 63689-100ML-F). RNA was purified using the AllPrep RNA / DNA Mini Kit (Qiagen Cat. No. 80204) and reverse transcribed to cDNA and preamplified using the High Capacity cDNA Kit (ThermoFisher Cat. No. 4368814), followed by TaqMan PCR. Analysis was performed using PreAmp Master Mix (ThermoFisher catalog number 4384557B). ThermoFisher ViiA7 Real-Time hTERT transcript levels were measured using a PCR system and products were analyzed using an in-house developed Taq-Man RT-qPCR assay (TaqMan Universal PCR Master Mix-ThermoFisher catalog number 4304437; primer and probe sequences below). hTERT full length forward: 5'-TGTACTTTGTCAAGGTGGATGTGA-3' (SEQ ID NO: 4) hTERT full length reverse: 5'-GCTGGAGGTCTGTCAAGGTAGAG-3' (SEQ ID NO: 5) hTERT FAM probe: FAM 5'-CGCGTACGACACCAT-3'MGBNFQ (SEQ ID NO: 6) Here, FAM is the fluorescent reporter and MGBNFQ is the quencher.
[0115] Bar graphs showing hTERT expression after 48 and 96 h of treatment with imetelstat sodium and / or ABT-199 are shown in Figure 9. RNA expression levels as measured by RT-qPCR are shown as a percentage of untreated controls at the same exposure times. Results show that KG-1 cells have a minimal decrease in hTERT RNA levels upon ABT-199 treatment (90-95% compared to control at either time point), while MOLM-13 cells show only a slight decrease in hTERT transcript levels after 96 h of dosing (approximately 69% compared to control). Imetelstat sodium treatment shows a greater decrease in RNA levels for both cell lines, with even lower expression at longer treatment times (KG-1 cells at 72% of control at 48 h and 47% of control at 96 h; MOLM-13 cells at 39% at 48 h and undetectable by the assay at 96 h). hTERT expression was unchanged for the combination of imetelstat sodium and ABT-199 compared to imetelstat sodium single agent in KG-1. hTERT was undetectable for MOLM-13 at both time points. hTERT enzyme levels
[0116] Samples from the above chapter on protein analysis were collected as cell pellets by centrifugation at 1500K for 5 min for lysis and protein extraction. A modified method was used to analyze the combined protein lysates from the two main sources (Hou, et al. (2001) 43(3) 519-524 and Nature Protocols (2006) 1 (3) 1583-1590). Lysates were made by adding 80 μl of 10 mM Tris-EDTA, 1% NP-40, 10% glycerol, 150 mM NaCl, 1 mM MgCl2, 250 μM sodium deoxycholate, 100 μM AEBSF, 5 mM 2-mercaptoethanol buffer and incubating on ice for 30 min. The lysates were centrifuged for 15 min at maximum speed at 4°C to pellet the cell debris. Protein yield from the cleared lysates was quantified using a BCA assay (ThermoFisher Cat. No. 23252) and relative telomerase activity was determined using a qPCR TRAP-based assay using ThermoFisher's ViiA7 Real-Time PCR System (Power SYBR Green PCR Master Mix-ThermoFisher No. 4367659). In this assay, protein lysates are exposed to synthetic oligonucleotides that mimic telomeric sequences in the presence of excess dNTPs and SYBR green dye. The greater the activity of telomerase, the greater the extension of the synthetic primer and therefore the greater the staining of the nucleic acid and the signal generated by the SYBR dye. This signal was compared to a standard curve of control protein lysates to determine the relative telomerase activity between samples. Forward primer: 5'-AATCCGTCGAGCAGAGTT-3' (SEQ ID NO: 7) Reverse primer: 5'-GCGCGGCTTACCCTTACCCTTACCCTAACC-3' (SEQ ID NO: 8) Molecular Interaction Results
[0117] Bar graphs showing telomerase activity after 48 and 96 hours of treatment with imetelstat sodium and / or ABT-199 are shown in FIG. 10. At 48 hours, ABT-199 shows no effect on telomerase activity when used as a single agent in both KG-1 and MOLM-13 cells. At 96 hours of ABT-199 treatment, telomerase activity was reduced to about 80% in KG-1 and about 70%, indicating that ABT-199 has little effect on telomerase activity. Imetelstat sodium showed a reduction in telomerase activity in both KG-1 and MOLM-13 cell lines. In MOLM-13 cells, the reduction compared to the control was comparable at both time points (37% at 48 hours and 44% at 96 hours). However, KG-1 showed a greater decrease in telomerase activity with 96 hours of imetelstat sodium treatment (64% at 48 hours and 16% at 96 hours). With combination therapy, KG-1 showed minimal difference from imetelstat sodium single agent, while in MOLM-13, the decrease in telomerase activity was nearly undetectable by PCR assay. Example 3: Elucidating combination synergy
[0118] Treatment of the AML tumor cell line MOLM-13 model was repeated in the experimental format described in Example 1 with the following modifications: Imetelstat sodium, control mismatched compound and control non-complementary compound were tested at higher concentrations from 0 to 75 μM (7 total concentrations) and ABT-199 was tested at 20 pM to 1 μM (9 total concentrations). Treated cells were analyzed by flow cytometry for Annexin V and Propidium Iodide staining as previously described. Events gated in the apoptotic population (Annexin V+ / Propidium Iodide+) were used to determine a synergy score for this combination matrix. Analysis of the combination data was performed using the Horizon Chalice TMThe data were generated by Analyzer Software (Horizon Discovery Group, Cambridge, UK). Further in vitro experiments were performed using MOLM-13 and cell line HL-60 to evaluate the synergy of imetelstat sodium and ABT-199 at a single exposure to this combination (i.e., 48 hours, no re-dosing). The ABT-199 dose range was slightly permuted (500 pM to 100 nM, five final concentrations) and compared to the equivalent data points in the experiment described above, where cells were dosed a second time at 48 hours. Mismatch and non-complementary controls were not used in this experiment.
[0119] To statistically qualify the effects observed in treated MOLM-13 cells, raw data from fixed dose ratios in an isobologram analysis were compiled according to the method of Chou and Talalay (Chou TC, Talalay P., Adv Enzyme Regul 1984; 22:27-55) using Horizon's Chalice. TM The Analyser Software web application was used to evaluate the drug combinations. The combination conditions were subjected to an isobologram analysis to generate a combination index, which plots the behavior of synergistic pairs that fall below this isobologram and antagonistic pairs that fall above it (additive combinations are expected to lie on this line). Horizon Chalice TM The Analyzer Software further provides a synergy score, with values greater than 1 indicating synergy.
[0120] A graph of % apoptotic cells (double label) versus ABT-199 concentration at various imetelstat sodium concentrations for 48 hour treatment is shown in Figure 11. Table 19 shows the greater than additivity (Loewe model) calculation results for each combination for MOLM-13 cells after 48 hour treatment. Values greater than 0 are found in the upper right quadrant of Table 19, while concentrations of ABT-199 are 20 nM or greater and concentrations of imetelstat sodium are 25 μM or greater. Horizon Chalice TM The Analyzer Software further provides a synergy score, with values greater than 1 indicating synergy. For cells treated with imetelstat sodium, after 48 hours, the synergy score was determined to be 5.12. This compares with scores of 0.22 and 0.41 for the mismatch and non-complementary controls, respectively (Tables 20 and 21). Graphs of % apoptotic cells (double-labeled) versus ABT-199 concentration at various imetelstat sodium concentrations for the 48 hour treatment are shown in Figures 12A and 12B for the mismatch and non-complementary controls, respectively. [Table 19] [Table 20] [Table 21]
[0121] A graph of % apoptotic cells (double label) versus ABT-199 concentration at various imetelstat sodium concentrations for 96 hours of treatment is shown in Figure 13. Table 22 shows the greater than additivity (Loewe model) calculations for each combination for MOLM-13 cells after 96 hours of treatment. Values greater than zero are found on the top right diagonal of Table 19. Surprisingly, even the lowest concentrations of ABT-199 (0.04 nM and 0.2 nM) show synergy with 50 μM and 75 μM imetelstat sodium, respectively, and the lowest concentrations of imetelstat sodium (1 μM and 5 μM) show synergy with 500 nM and 100 nM ABT-199, respectively. Horizon Chalice TM The Analyzer Software further provides a synergy score, with values greater than 1 indicating synergy. For cells treated with imetelstat sodium, after 96 hours, the synergy score was determined to be 11.33. This compares with scores of 0.03 and 0.06 for the mismatch and non-complementary controls, respectively (Table 23 and Table 24). Graphs of % apoptotic cells (double labeled) versus ABT-199 concentration at various imetelstat sodium concentrations for the 96 hour treatment are shown in Figures 14A and 14B for the mismatch and non-complementary controls, respectively. [Table 22] [Table 23] [Table 24]
[0122] Apoptotic populations (double label) 96 hours after single dose treatment are shown for MOLM-13 (FIG. 17A) and AML cell line HL-60 (FIG. 17B). A smaller dose range of ABT-199 was used in this experiment to evaluate the efficacy of imetelstat sodium co-treatment. Table 25 shows the apoptotic populations (double label) after 96 hours of single dose treatment for MOLM-13 (FIG. 17A) and AML cell line HL-60 (FIG. 17B). A smaller dose range of ABT-199 was used in this experiment to evaluate the efficacy of imetelstat sodium co-treatment. Table 25 shows the apoptotic populations (double label) after single dose treatment for each MOLM-13 combination. TM Table 25 shows the greater than additivity (Loewe model) calculated by the Analyzer Software, while Table 26 shows the calculated results for HL-60. Although synergistic in both strains, greater synergy is observed in MOLM-13 as demonstrated by the greater scores and enhanced effect on apoptosis at lower (5 μM and 10 μM) imetelstat sodium concentrations. Combination with imetelstat sodium shows promise for lowering ABT-199 concentrations down to 1-5 nM doses. [Table 25] [Table 26]
[0123] For comparison, the data plotted in Figure 13 and used to generate Table 22 were compared with Horizon Chalice IV only at the doses used in Figure 17A and Table 25. TM The results were reanalyzed using the Analyzer Software. As shown in Table 27, the synergy score was nearly halved (11.33 to 6.06) when the upper levels of the ABT-199 titration curve were removed. This score was nearly double that of the 96-hour single dose (Table 25) condition (6.06 vs. 3.24), suggesting that sequential exposure induces even greater synergy when ABT-199 and imetelstat sodium are combined. [Table 27] Example 4: Combining the telomerase inhibitor imetelstat sodium with the BCL-2 inhibitor venetoclax enhances apoptosis in AML patient samples ex vivo.
[0124] Acute myeloid leukemia (AML) is an aggressive cancer with limited treatment options other than chemotherapy, and thus a curative agent is needed to fulfill this unmet need. Both hTERT (catalytic subunit of telomerase) and BCL-2 (apoptosis regulator) are overexpressed in AML, which correlates with disease severity and poor prognosis, respectively. Imetelstat sodium is a first-in-class competitive inhibitor of telomerase with clinical activity in hematological malignancies. Venetoclax (ABT-199) is a BCL-2 inhibitor approved for CLL patients lacking 17p and who have received at least one previous therapy, and has shown promising clinical benefit in AML patients. The study in this example investigated the effect of imetelstat sodium or venetoclax alone or in combination on AML cells in vitro.
[0125] AML cell lines (see Example 1) and AML patient peripheral blood mononuclear cell ("PBMC") samples obtained from AML patient whole blood after Ficoll purification were treated with imetelstat sodium or venetoclax alone or in combination, and viable and apoptotic cell populations were assessed by flow cytometry. Telomerase activity, hTERT expression and mitochondrial dysfunction were investigated for mechanism of action. AML patient PBMCs were dosed with imetelstat sodium (0 μM, 25 μM and 50 μM), venetoclax (ABT-199) (0 nM, 20 nM and 100 nM) or combination for 16 or 40 hours. Apoptosis was measured by flow cytometric staining for Annexin V and propidium iodide. Unstained (i.e. double negative) cells constitute viable cells remaining after treatment.
[0126] Specifically, whole blood from AML patients (n=4) was purified using Ficoll-Paque Plus (GE Healthcare catalog no. 17-1440-03) to purify PBMCs. Ficoll was placed in a 50mL SepMate centrifuge tube (StemCell Technologies catalog no. 85450), and the patient's blood was diluted 1:1 with phosphate-buffered saline (PBS; ThermoFisher catalog no. 20012-027) supplemented with 2% FBS in HyClone fetal bovine serum (FBS) (ThermoFisher catalog no. SH30070.02) and then loaded on top of the Ficoll. The blood was centrifuged to separate PBMCs from red blood cells, granulocytes, etc., and the remaining PBMCs were washed twice with PBS + 2% FBS. Cells were plated in 96-well polystyrene U-bottom tissue culture plates (Corning catalog 353777) at a density of approximately 300,000 cells per well in RPMI-1640 supplemented with 10% HyClone FBS (ThermoFisher catalog no. 11875-085) as described above and grown in a humidified 37°C incubator with 5% CO2. No antibiotics were used with ex vivo PBMCs. Cells were immediately treated with imetelstat sodium (Janssen Biotech, Inc.) prepared in RPMI-1640 supplemented with 10% FBS and / or ABT-199 (Selleckchem catalog no. S8048) prepared as a 1000x stock in DMSO and diluted 1:100 in PBS (vehicle). Imetelstat sodium was tested from 0 to 50 μM and venetoclax (ABT-199) was tested from 0 to 100 nM.
[0127] After 16 and 40 hours of treatment, cells were measured for healthy, early apoptotic and apoptotic populations using Annexin V (an internal cell membrane stain) and Propidium Iodide (PI, a dye that binds DNA) flow cytometry assay kits (BioLegend catalog 640914) as described in Example 1. Additionally, PBMCs were stained for the following differentiation markers: CD45 (V500 conjugated; BD catalog no. 560777) and CD34 (Pacific Blue conjugated; Biolegend catalog no. 343512). Events were first gated for CD45 positivity and then gated for CD34 before Annexin V / Propidium Iodide evaluation as described in Example 1 above. CD45 + (white blood cells) and CD45 + / CD34 + For the (leukemic stem cell) population, the mean and standard deviation of the four patients were determined. Ex vivo treatment outcomes
[0128] Figures 15A-15D show the mean responses of PBMC samples from four AML patients exposed ex vivo to imetelstat sodium and / or venetoclax (ABT-199). + Leukocytes and CD45 + / CD34 + Leukemia stem cells were treated with various concentrations of venetoclax (ABT-199) and / or imetelstat sodium for 16 hours. The graph of % viable cells after treatment is shown in Figure 15A (CD45 + leukocytes) and 15B (CD45 + / CD34 + Leukemia stem cells) in AML patients. + Leukocytes and CD45 + / CD34 + Leukemia stem cells were treated with various concentrations of venetoclax (ABT-199) and / or imetelstat sodium for 40 hours. The graph of % viable cells after treatment is shown in Figure 15C (CD45 + leukocytes) and 15D (CD45 + / CD34 + Leukemia stem cells) are shown. Generally, CD45 + Leukocyte viability was not affected by imetelstat sodium treatment alone and only moderately affected by venetoclax as a single agent after 16 and 40 hours of exposure. However, a decrease in cell viability was observed when imetelstat sodium was used in combination with venetoclax. CD45 + / CD34 + Similar results were observed for leukemia stem cell populations. Imetelstat sodium in combination with venetoclax showed dose-dependent activity in reducing cell viability at both time points, most notable at 40 hours.
[0129] When imetelstat sodium and venetoclax were combined, a dose-dependent synergistic activity in apoptosis induction was observed in multiple AML cell lines (see Example 1). For example, in MOLM-13 cell line, single agent imetelstat sodium and venetoclax had moderate apoptosis activity after 48 hours (22% and 30%, respectively), but the combination achieved 88% at 48 hours and nearly 100% at 96 hours. Similar enhanced apoptosis activity was also observed in four AML patient samples. Molecular analysis showed that combining imetelstat sodium and venetoclax reduced hTERT expression and enhanced telomerase activity more than either agent alone. This example shows that combining imetelstat sodium and venetoclax in AML has a synergistic effect on apoptosis induction in cell lines and patient samples in vitro. Example 5: Combining the telomerase inhibitor imetelstat sodium with the BCL-2 inhibitor venetoclax enhances survival in acute myeloid leukemia in vivo.
[0130] As described in Example 4, acute myeloid leukemia (AML) is an aggressive cancer with limited treatment options other than chemotherapy, and therefore, a curative agent is needed. Example 4 showed that the telomerase inhibitor imetelstat sodium, when combined with the BCL-2 inhibitor venetoclax, enhanced apoptosis in vitro. The studies in this example investigated the effect of imetelstat sodium or venetoclax alone, or in combination, in an in vivo model of acute myeloid leukemia. method
[0131] In vivo studies in a mouse model seeded with MOLM-13 AML were performed to evaluate efficacy and survival. Specifically, mice were implanted with MOLM-13 AML tumor cells on study day 0. Mice were treated for 31 days with: (i) vehicle (MM+PEG400 / Phosal50 / ETOH); (ii) imetelstat sodium (30 mg / kg); (iii) venetoclax (ABT-199) (100 mg / kg); (iv) MM (mismatch oligonucleotide control) (30 mg / kg) and ABT-199 (100 mg / kg); and (v) imetelstat sodium (30 mg / kg) and ABT-199 (100 mg / kg). Mice survival was evaluated as a function of time (days after tumor cell implantation). The study lasted a total of 108 days (77 days after treatment was stopped).
[0132] Fifty female SCID beige mice (6 weeks old, Jackson Laboratory) were injected intravenously with 1 million MOLM-13 cells and randomly divided into 5 groups. One day after injection, the mice were treated with one of the five conditions listed in Table 28. [Table 28]
[0133] Mice were observed daily and body weights were measured twice a week. The survival of mice in each group was also followed. The study was terminated on day 108, which was 77 days after the last treatment. Increased longevity ("ILS") was assessed for each group and expressed as % ILS relative to vehicle control. ILS%=100×(TC) / C where T is the median survival in the treatment group and C is the median survival in the control group. In vivo test results
[0134] Kaplan-Meier Survival Plot of the AML disseminated model MOLM-13 at day 108 is shown in FIG. 16. In particular, FIG. 16 shows the survival rate of mice as a function of days after tumor cell implantation. The median survival and percent increased lifespan ("ILS") calculated for the various treatment groups are shown in Table 29. The results show that the median survival time for mice treated with imetelstat sodium single agent was 26.5 days, which translates to 20.4% ILS (p=0.0009) compared to vehicle. Treatment with venetoclax (ABT-199) single agent resulted in a median survival time of 30 days and an ILC of 36.3% (p≦0.0001). When combined with mismatched (MM) oligo control, ABT-199 provided similar efficacy to ABT-199 alone. Median survival time 31 days, ILS 40.9% (p≦0.0001). The best results were obtained by combining imetelstat sodium with ABT-199, with a median survival time of 37 days and a significant efficacy of 68.1% ILS (p≦0.0001). Furthermore, 4 mice (40%) from this combination therapy group survived longer, surviving for more than 108 days, indicating an enhanced survival benefit. [Table 29]
[0135] All mice tolerated the combination of imetelstat sodium and venetoclax, and increased lifespan was observed when compared to imetelstat sodium (39.6%, p=0.0011) or venetoclax (23.3%, p=0.0001) alone. In this combination group, 40% of treated mice were alive 77 days after treatment was discontinued, indicating a significant survival benefit with potential cure. The results in this example, as in Example 4, show that in AML, the combination of imetelstat sodium and venetoclax has a synergistic effect on apoptosis induction in cell lines and patient samples in vitro, which translates to long-term survival and potential cure in xenograft models. Equivalents and Incorporation by Reference
[0136] Although the present invention has been described with reference to specific embodiments thereof, it should be understood by those skilled in the art that various modifications may be made and equivalents may be substituted without departing from the scope of the present invention. In addition, many modifications may be made to adapt to a particular situation, material, composition of matter, process, process step or steps, in order to achieve the benefits provided by the present invention without departing from the scope of the invention. All such modifications are intended to be included within the scope of the appended claims.
[0137] All publications and patent documents cited herein are incorporated by reference herein as if each such publication or document was specifically and individually indicated to be incorporated by reference herein. Citation of publications and patent documents is not intended to indicate that any such document is pertinent prior art, nor does it constitute an admission as to the contents or date thereof. The present invention provides, for example, the following items. (Item 1) 1. A method of treating a hematological cancer, comprising administering to a subject in need of treatment a combination of a telomerase inhibitor and a Bcl-2 inhibitor. (Item 2) The blood cancer is acute myeloid leukemia, essential thrombocythemia, polycythemia vera, primary myelofibrosis, systemic mastocytosis, chronic myeloid leukemia, chronic neutrophilic leukemia, chronic eosinophilic leukemia, refractory anemia with ringed sideroblasts, refractory cytopenia with polycythemia dysplasia, refractory anemia with excess blasts (type 1), refractory anemia with excess blasts (type 2), myelodysplastic syndrome (MDS) with isolated deletion of the long arm of chromosome 5 (5q), unclassifiable MDS, chronic myelomonocytic leukemia (CML), atypical chronic myeloid leukemia, juvenile myelomonocytic leukemia, unclassifiable myeloproliferative / myelodysplastic syndrome, B lymphoblastic leukemia / lymphoma, T lymphoblastic leukemia / lymphoma, diffuse large intestine ... 2. The method according to item 1, wherein the tumor is selected from the group consisting of B-cell lymphoma, primary central nervous system lymphoma, primary mediastinal B-cell lymphoma, Burkitt's lymphoma / leukemia, follicular lymphoma, chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma, B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma / Waldenström's macroglobulinemia, mantle cell lymphoma, marginal zone lymphoma, post-transplant lymphoproliferative disorder, HIV-associated lymphoma, primary effusion lymphoma, intravascular large B-cell lymphoma, primary cutaneous B-cell lymphoma, hairy cell leukemia, monoclonal gammopathy of undetermined significance, smoldering multiple myeloma and solitary plasmacytoma (solitary bone and extramedullary). (Item 3) 2. The method of claim 1, wherein the blood cancer is acute myeloid leukemia. (Item 4) 4. The method according to any one of items 1 to 3, wherein the telomerase inhibitor is imetelstat. (Item 5) Imetelstat is administered in 1, 2, 3, 4, 5, 6, 7, 8, or more than 8 dosing cycles, each cycle comprising: (a) Approximately 7-10 mg / kg of imetelstat administered intravenously once every 4 weeks; (b) approximately 7-10 mg / kg of imetelstat administered intravenously once weekly for 4 weeks; (c) about 2.5 to 10 mg / kg of imetelstat administered intravenously once every three weeks; or (d) The method according to item 4, comprising intravenously administering about 0.5 to 9.4 mg / kg of imetelstat once every 4 weeks. (Item 6) 6. The method of claim 5, wherein said imetelstat is imetelstat sodium. (Item 7) 7. The method according to any one of items 1 to 6, wherein the Bcl-2 inhibitor is ABT-199. (Item 8) ABT-199, (a) at a dose of approximately 50-400 mg of ABT-199 daily; (b) a dose of about 2 mg of ABT-199 on day 1, then increasing daily until a final dose of about 800 mg on day 6, and then at that final dose daily thereafter; or (c) a dose of approximately 25 mg of ABT-199 on day 1, then increasing daily until a final dose of approximately 400 mg on day 5, and then daily thereafter The method of claim 7, wherein the dose is administered in a single dose. (Item 9) 9. The method of claim 8, wherein the administration of ABT-199 is one day before, one day after, or on the same day as the administration of the telomerase inhibitor. (Item 10) A method for inducing apoptosis in a hematological cancer cell, the method comprising contacting the cell with a therapeutically effective amount of a telomerase inhibitor and contacting the cell with a therapeutically effective amount of a Bcl-2 inhibitor. (Item 11) 11. The method of claim 10, wherein the telomerase inhibitor is imetelstat. (Item 12) 12. The method of claim 11, wherein the imetelstat is imetelstat sodium. (Item 13) 13. The method according to any of items 10 to 12, wherein the Bcl-2 inhibitor is ABT-199. (Item 14) The blood cancer cells are selected from acute myeloid leukemia, essential thrombocythemia, polycythemia vera, primary myelofibrosis, systemic mastocytosis, chronic myeloid leukemia, chronic neutrophilic leukemia, chronic eosinophilic leukemia, refractory anemia with ringed sideroblasts, refractory cytopenia with polycythemia dysplasia, refractory anemia with excess blasts (type 1), refractory anemia with excess blasts (type 2), myelodysplastic syndrome (MDS) with isolated deletion of the long arm of chromosome 5 (5q), unclassifiable MDS, chronic myelomonocytic leukemia (CML), atypical chronic myeloid leukemia, juvenile myelomonocytic leukemia, unclassifiable myeloproliferative / myelodysplastic syndrome, B lymphoblastic leukemia / lymphoma, T lymphoblastic leukemia / lymphoma, diffuse large B-cell lymphoma, or diffuse large B-cell lymphoma. 11. The method according to item 10, wherein the cell is selected from the group consisting of lymphoma, primary central nervous system lymphoma, primary mediastinal B-cell lymphoma, Burkitt's lymphoma / leukemia, follicular lymphoma, chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma, B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma / Waldenstrom's macroglobulinemia, mantle cell lymphoma, marginal zone lymphoma, post-transplant lymphoproliferative disorder, HIV-associated lymphoma, primary effusion lymphoma, intravascular large B-cell lymphoma, primary cutaneous B-cell lymphoma, hairy cell leukemia, monoclonal gammopathy of undetermined significance, smoldering multiple myeloma and solitary plasmacytoma (solitary bone and extramedullary) types of blood cancer. (Item 15) The method of claim 10, wherein the blood cancer cells are acute myeloid leukemia (AML) cells. A kit comprising: (a) a dose of a telomerase inhibitor in an amount effective when administered to induce apoptosis in hematological cancer cells; (b) a Bcl-2 inhibitor in a dose effective to induce apoptosis in blood cancer cells when administered. (Item 17) 17. The kit of item 16, wherein the telomerase inhibitor is imetelstat and the Bcl-2 inhibitor is ABT-199. (Item 18) 1. A method of treating acute myeloid leukemia, comprising administering imetelstat and ABT-199 to a subject with acute myeloid leukemia. (Item 19) 1. An in vitro method of inducing apoptosis in acute myeloid leukemia (AML) cells, comprising contacting the cells with a therapeutically effective amount of imetelstat sodium and contacting the cells with a therapeutically effective amount of ABT-199. (Item 20) A pharmaceutical composition comprising imetelstat and ABT-199. (Item 21) 21. The pharmaceutical composition of item 20, wherein the imetelstat is imetelstat sodium. (Item 22) 21. The pharmaceutical composition of item 20, wherein the composition is formulated for the treatment of acute myeloid leukemia. (Item 23) Use of imetelstat or imetelstat sodium to treat hematological cancers in patients receiving BCL inhibitor therapy. (Item 24) Use of ABT-199 to treat hematological cancers in patients receiving telomerase inhibitor therapy. (Item 25) 1. A telomerase inhibitor for use in a method of treating a blood cancer, the method comprising administering to a subject in need of treatment said telomerase inhibitor in combination with a Bcl-2 inhibitor. (Item 26) 1. A combination comprising a telomerase inhibitor and a Bcl-2 inhibitor for use in a method of treating a blood cancer, the method comprising administering the combination to a subject in need of treatment. (Item 27) The blood cancer is acute myeloid leukemia (AML), essential thrombocythemia, polycythemia vera, primary myelofibrosis, systemic mastocytosis, chronic myeloid leukemia, chronic neutrophilic leukemia, chronic eosinophilic leukemia, refractory anemia with ringed sideroblasts, refractory cytopenia with polycythemia dysplasia, refractory anemia with excess blasts (type 1), refractory anemia with excess blasts (type 2), myelodysplastic syndrome (MDS) with isolated deletion of the long arm of chromosome 5 (5q), unclassifiable MDS, chronic myelomonocytic leukemia (CML), atypical chronic myeloid leukemia, juvenile myelomonocytic leukemia, unclassifiable myeloproliferative / myelodysplastic syndrome, B lymphoblastic leukemia / lymphoma, T lymphoblastic leukemia / lymphoma, diffuse large B-cell lymphoma, primary central nervous system 27. The telomerase inhibitor for use according to item 25 or the combination for use according to item 26, wherein the tumor is a lymphoma of the nervous system, primary mediastinal B-cell lymphoma, Burkitt's lymphoma / leukemia, follicular lymphoma, chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma, B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma / Waldenström's macroglobulinemia, mantle cell lymphoma, marginal zone lymphoma, post-transplant lymphoproliferative disorder, HIV-associated lymphoma, primary effusion lymphoma, intravascular large B-cell lymphoma, primary cutaneous B-cell lymphoma, hairy cell leukemia, monoclonal gammopathy of undetermined significance, smoldering multiple myeloma and solitary plasmacytoma (solitary bone and extramedullary). (Item 28) 27. The telomerase inhibitor for use according to item 25 or the combination for use according to item 26, wherein the blood cancer is acute myeloid leukemia. (Item 29) 27. The telomerase inhibitor for use according to item 25 or the combination for use according to item 26, wherein the telomerase inhibitor is imetelstat. (Item 30) 30. The telomerase inhibitor for use according to item 29 or the combination for use according to item 29, wherein the telomerase inhibitor is imetelstat sodium. (Item 31) Imetelstat is administered for administration of 1, 2, 3, 4, 5, 6, 7, 8, or more than 8 dosing cycles, each cycle comprising: (a) Approximately 7-10 mg / kg of imetelstat administered intravenously once every 4 weeks; (b) approximately 7-10 mg / kg of imetelstat administered intravenously once weekly for four weeks; or (c) about 2.5 to 7 mg / kg of imetelstat administered intravenously once every 3 weeks; or (c) A telomerase inhibitor for use according to item 29 or a combination for use according to item 29, comprising about 0.5 to 9.4 mg / kg of imetelstat administered intravenously once every 4 weeks. (Item 32) 27. The telomerase inhibitor for use according to item 25 or the combination for use according to item 26, wherein the Bcl-2 inhibitor is ABT-199. (Item 33) The ABT-199 (a) at a dose of 50–400 mg of ABT-199 daily; (b) a dose of 2 mg of ABT-199 on day 1, then increasing daily until a final dose of 800 mg on day 6, and then at that final dose daily thereafter; (c) A telomerase inhibitor for use according to item 32 or a combination for use according to item 32, to be administered at a dose of 25 mg of ABT-199 on day 1, followed by daily increasing doses up to a final dose of 400 mg on day 5, and every day thereafter at that final dose. (Item 34) 27. The telomerase inhibitor for use according to item 25 or the combination for use according to item 26, wherein the administration of ABT-199 is one day before, one day after, or on the same day as the administration of the telomerase inhibitor. (Item 35) 27. The telomerase inhibitor for use according to item 25 or the combination for use according to item 26, wherein said combination of a telomerase inhibitor with a Bcl-2 inhibitor induces apoptosis of blood cancer cells. (Item 36) 1. Imetelstat sodium for use in a method for treating acute myeloid leukemia (AML), the method comprising administering imetelstat sodium in combination with ABT-199 to a subject in need of treatment. (Item 37) ABT-199 for use in a method for treating acute myeloid leukemia (AML), the method comprising administering ABT-199 in combination with imetelstat sodium to a subject in need of treatment. (Item 38) A combination comprising imetelstat sodium and ABT-199 for use in a method for treating acute myeloid leukemia (AML), the method comprising administering the combination to a subject in need of treatment. (Item 39) The imetelstat sodium is for administration for 1, 2, 3, 4, 5, 6, 7, 8, or more than 8 dosing cycles, each cycle comprising: (a) Approximately 7 to 10 mg / kg of imetelstat sodium administered intravenously once every 4 weeks; (b) approximately 7 to 10 mg / kg of imetelstat sodium administered intravenously once weekly for 4 weeks; (c) about 2.5 to 7 mg / kg of imetelstat sodium administered intravenously once every 3 weeks; or (d) A telomerase inhibitor for use according to item 36, ABT-99 for use according to item 37, or the combination for use according to item 38, comprising about 0.5 to 9.4 mg / kg of imetelstat sodium administered intravenously once every 4 weeks. (Item 40) The ABT-199 (a) at a dose of approximately 50-400 mg of ABT-199 daily; (b) a dose of about 2 mg of ABT-199 on day 1, increased daily thereafter to a final dose of about 800 mg on day 6, and then at that final dose daily thereafter; (c) Imetelstat sodium for use according to item 36, ABT-99 for use according to item 37, or the combination for use according to item 38, to be administered at a dose of about 25 mg of ABT-199 on day 1, increasing daily thereafter to a final dose of about 400 mg on day 5, and at that final dose every day thereafter. (Item 41) 39. The combination for use according to item 36, wherein said administration of ABT-199 is one day before, one day after, or on the same day as said administration of imetelstat sodium.
Claims
[Claim 1] The invention described in the specification.
Citation Information
Patent Citations
Use of telomerase inhibitors to treat myeloproliferative diseases and neoplasms
JP2016504307A
